_pmid,_doi,_publicationTitle,_year,_toolName,_toolType,_usageType,publicationId,resourceId,usageId
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,spheroid culture system,advanced_cellular_models,Experimental Usage,PUB36730269,REScbf4cfbd,USE7223b586
PMID:40862755,10.3390/cells14161276,Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.,,TAME chips,advanced_cellular_models,Experimental Usage,PUB40862755,RES02bbf891,USE4cef23bc
PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,3D rBM overlay model,advanced_cellular_models,Experimental Usage,PUB39061138,RES7826f166,USEfc6b5b32
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,cNF organoids,advanced_cellular_models,Development,PUB38744290,RESe4a3a14d,USE7b3a0948
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,129T2/SvEmsJ::C57Bl/6NTac Nf1+/- and Nf1+/+,animal_models,Experimental Usage,PUB31545171,RES60a30c1c,USE62b54b5c
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,C57BL6/J Nf1+/−;Trp53+/−,animal_models,Experimental Usage,PUB32642734,RES6701a540,USE883ac5d3
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,Nf1 c.5425 C > T ; Arg1809Cys,animal_models,Experimental Usage,PUB35589737,RES5c29d488,USEee32315c
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,R681X Nf1,animal_models,Experimental Usage,PUB35589737,RES37d0d0f4,USEe0d24e96
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,Nf1 flox/flox ; Hoxb7-Cre,animal_models,Experimental Usage,PUB35589737,RESe1e3fe79,USE454f25f1
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,Nf1 f/neo ; hGFAP-Cre,animal_models,Experimental Usage,PUB35589737,RES9aecdcd6,USE64012ff3
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,Nf1-IF,animal_models,Experimental Usage,PUB38216123,RESae80970f,USE17b91ad5
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,Nf1-PS,animal_models,Experimental Usage,PUB38216123,RES95b54f21,USEc7739321
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,Nf1-IFPS,animal_models,Experimental Usage,PUB38216123,RES3a69c7aa,USE08e76506
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,Nf1(ob) (-/-),animal_models,Experimental Usage,PUB20200958,RES316daddd,USE908d4c4a
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,2.3-kb α1(I) collagen-cre Nf1 flox/flox,animal_models,Experimental Usage,PUB20200958,RES73ca456b,USE96e7bcdc
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,Nf1 flox/flox,animal_models,Experimental Usage,PUB20200958,RESbf0146a3,USE50efd142
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,Nf1 flox,animal_models,Experimental Usage,PUB33078583,RESd390084f,USE8f4411b0
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,,Nf1+/-,animal_models,Experimental Usage,PUB32781282,RESd867fbf0,USEb7f29526
PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,y w Mer4,animal_models,Experimental Usage,PUB24595234,RES6e23a044,USE4ad67f29
PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,4/FM7; T80-Gal4 y w Mer4,animal_models,Experimental Usage,PUB24595234,RES25632977,USEd4ac9002
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,PLP CreERT2; Nf1 f/−; ROSA-LacZ,animal_models,Experimental Usage,PUB30479396,RESe57e7070,USE953cb54b
PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,Nf1Prx1,animal_models,Experimental Usage,PUB21726432,RESe475a58f,USE6fabd76a
PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,Nf1flox,animal_models,Experimental Usage,PUB21726432,RESd390084f,USE4a742472
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,Nf1flox/flox,animal_models,Experimental Usage,PUB19191334,RESbf0146a3,USEf1a3b2a1
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,Nf1GFAP CKO,animal_models,Experimental Usage,PUB19191334,RESfd454e78,USEed7571a2
PMID:23225063,10.1002/ana.23793,Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice.,,Nf1 +/− GFAP CKO,animal_models,Experimental Usage,PUB23225063,RESfd454e78,USE84027956
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,Nf1+/-,animal_models,Experimental Usage,PUB21199799,RESd867fbf0,USEeba32a92
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,,Nf1(flox/-);Col2.3Cre(+),animal_models,Development,PUB21439418,RES22a66b69,USEb1691f85
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,,Nf1 +/−,animal_models,Experimental Usage,PUB21439418,RESd867fbf0,USE5f082cb9
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,,Nf1 flox/flox,animal_models,Experimental Usage,PUB21439418,RESbf0146a3,USE56b3e949
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,cisNP,animal_models,Experimental Usage,PUB38502231,RES8010fe38,USE65f8668e
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,y [1] sc[*] v [1] sev [21]; P{y[+t7.7] v[+t1.8] = TKO.GS01796}attP40,animal_models,Experimental Usage,PUB39129390,RES64a05ee5,USE460e3b8c
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,P{ KK101909 }VIE‐260B,animal_models,Experimental Usage,PUB39129390,RES01f5e8c7,USEd9d6d4ea
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,Nf1Dsk9/+,animal_models,Experimental Usage,PUB30571760,RESbb21f572,USEc043fbbf
PMID:29408605,10.1016/j.neuroscience.2018.01.054,Nf2 Mutation in Schwann Cells Delays Functional Neural Recovery Following Injury.,,P0SchΔ39-121,animal_models,Experimental Usage,PUB29408605,RESb805ba75,USEa2b8dd36
PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,"Trp53, Nf1, Suz12 triple mutant",animal_models,Experimental Usage,PUB38931352,RES9f0896d4,USE33ec900f
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,Nf1flox/flox;PostnCre,animal_models,Experimental Usage,PUB33442015,RES971399c4,USE90a09fa8
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,NF1 fl/fl Tp53 fl/fl Eed fl/fl;Dhh-Cre,animal_models,Experimental Usage,PUB36322658,RESb8ec4fc0,USEa1609eeb
PMID:21551250,10.1158/0008-5472.CAN-10-4577,Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development.,,NF1 flox/−,animal_models,Experimental Usage,PUB21551250,RESd390084f,USEb471afc8
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,NF1 R1947/+,animal_models,Development,PUB37520682,RES136a6220,USEf08d1362
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,Nf1fl/fl,animal_models,Experimental Usage,PUB34040258,RES0178a4cc,USE7c7cbd03
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,OPG Nf1fl/mut (Nf1+/−),animal_models,Experimental Usage,PUB34040258,RESf2783b89,USE235d47c2
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,Nf1+/- mice,animal_models,Experimental Usage,PUB21949590,RESd867fbf0,USE2487d635
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,Nf1 hGFAP CKO,animal_models,Experimental Usage,PUB22901811,RES644113d0,USE7c4b5b58
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,Nf1 NcreER CKO,animal_models,Experimental Usage,PUB22901811,RES5b5f1511,USE7b86486c
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,Nf1+/–,animal_models,Experimental Usage,PUB40590220,RESd867fbf0,USE76f8a7a6
PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,Nf1 flox,animal_models,Experimental Usage,PUB21681782,RESd390084f,USE7ca39acc
PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,Nf1 fcr,animal_models,Experimental Usage,PUB21681782,RES4cf34317,USEbe1b1ce6
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,Nf1 ±,animal_models,Experimental Usage,PUB36890585,RESd867fbf0,USE79c0d2a8
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,Nf1 flox/flox,animal_models,Experimental Usage,PUB36890585,RESbf0146a3,USE47be1baf
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,NPcis,animal_models,Experimental Usage,PUB36730269,RESf5e1c690,USEde9653c8
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,"Nf1 flox/mut; GFAP-Cre, Nf1+/− GFAP CKO",animal_models,Experimental Usage,PUB20554030,RES9a06a62f,USEa6e58b8f
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,Postn-Cre; Nf2flox/flox,animal_models,Experimental Usage,PUB41444363,RESbcbdd0d7,USE97ef063a
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,Nf2flox/flox,animal_models,Experimental Usage,PUB41444363,RES173e403d,USEb9702b44
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,"Dhh::Cre, Nf1fl/fl, Pten",animal_models,Experimental Usage,PUB41036607,RES67640ce9,USEd16cef53
PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,Nf1^flox/flox;GFAP-Cre,animal_models,Experimental Usage,PUB26883872,RESd6ee208c,USE711f7fe0
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,,DhhCre;Nf1fl/fl,animal_models,Experimental Usage,PUB28029918,RES41704967,USE263e15ab
PMID:24465906,10.1371/journal.pone.0086115,"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.",,Nf1Prx1,animal_models,Experimental Usage,PUB24465906,RESe475a58f,USE01cc9669
PMID:24465906,10.1371/journal.pone.0086115,"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.",,Nf1Col1,animal_models,Experimental Usage,PUB24465906,RES3dbffed8,USEc3b6774a
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,Nf1(fl/fl);DhhCre,animal_models,Experimental Usage,PUB26904939,RES5d4d846e,USEe01e680b
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,Stat3(fl/fl);Nf1(fl/fl);DhhCre,animal_models,Experimental Usage,PUB26904939,RES1e67bb5c,USE7b2959a7
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,Nf1f/f;Trp53f/f;Nes-TK,animal_models,Experimental Usage,PUB34010628,RES92440303,USEff66b6af
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,Nf1f/f;Trp53f/f;CGD,animal_models,Experimental Usage,PUB34010628,RESe1def87b,USE05a596dd
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,cisNP,animal_models,Experimental Usage,PUB34010628,RES8010fe38,USE6a1a3f5e
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,Nf1-/-,animal_models,Experimental Usage,PUB18242513,RESd867fbf0,USEc2f6d6c0
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,Nf1fl,animal_models,Experimental Usage,PUB18242513,RESd738ed2d,USE39cae5f3
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,Nf1/p53-/-,animal_models,Experimental Usage,PUB18242513,RESd995ff0b,USE3ec7523c
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,Nf1 flox/flox; GFAP-Cre,animal_models,Experimental Usage,PUB21216928,RESd6ee208c,USE4aa5cc7f
PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,9a−/9a− Nf1,animal_models,Experimental Usage,PUB25917366,RES53af612e,USEc41d9803
PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,9a−/9a+ Nf1,animal_models,Experimental Usage,PUB25917366,RES53af612e,USE34448a54
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,Nf1fl/fl;DhhCre,animal_models,Experimental Usage,PUB28256556,RES635e34f6,USE411adad5
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,Nf1flox/flox,animal_models,Experimental Usage,PUB40684195,RESbf0146a3,USEb99f5f38
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,Nf1+/−,animal_models,Experimental Usage,PUB40684195,RESd867fbf0,USEe95fb11e
PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,,Nf2 flox2/flox2,animal_models,Experimental Usage,PUB17924978,RESaff140e0,USEd818cc6f
PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,,Nf2 flox2/flox2 ;p16 Ink4a*/*,animal_models,Experimental Usage,PUB17924978,REScbe4b7bf,USE229824ed
PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,H7;Nf1mut,animal_models,Experimental Usage,PUB37140985,RES51beed64,USE0da1cfca
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,Nf1^flox/flox;GFAP-Cre,animal_models,Experimental Usage,PUB20551058,RESd6ee208c,USE921f58fe
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,Nf1^flox/mut;GFAP-Cre,animal_models,Experimental Usage,PUB20551058,RESb35d7371,USE2c107fe7
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,DhhCre,animal_models,Experimental Usage,PUB38127282,RES3195007c,USE868ec6be
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,Nf1flox/flox;PostnCre+,animal_models,Experimental Usage,PUB38127282,RES971399c4,USE7ac9dbd8
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,Nf1flox/flox;Arf flox/flox;PostnCre+,animal_models,Experimental Usage,PUB38127282,RES167f736f,USEad75793d
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,Nf1+/−,animal_models,Experimental Usage,PUB28525381,RESd867fbf0,USEb3a4f4b0
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,Nf1flox/wt,animal_models,Experimental Usage,PUB28525381,RES7a15e78d,USE1b40e576
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,Nf1flox/mut,animal_models,Experimental Usage,PUB28525381,RESc3e4f29b,USEdfb9d814
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,Nf1flox/flox; Olig2-Cre,animal_models,Experimental Usage,PUB28525381,RES027c26cd,USE444af014
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,Nf1flox/mut; Olig2-Cre,animal_models,Experimental Usage,PUB28525381,RESdab9bd29,USEaddbdcb8
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,Nf1flox/mut; GFAP-Cre,animal_models,Experimental Usage,PUB28525381,RESb35d7371,USEde0b766e
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,Nf1flox/flox,animal_models,Experimental Usage,PUB28525381,RESbf0146a3,USE431b842f
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,Nf1flox/flox; Prom1-CreER,animal_models,Experimental Usage,PUB28525381,RES94bdb445,USEe96054b6
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,Nf1flox/mut; Prom1-CreER,animal_models,Experimental Usage,PUB28525381,RESfdb125d4,USE12885d7e
PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of",,Nf1flox/flox;PostnCre+,animal_models,Experimental Usage,PUB31527226,RES971399c4,USE7bacbf8e
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,Periostin-CRE;NF2 fl/fl,animal_models,Experimental Usage,PUB36148553,RESa5ded38d,USE826fcb26
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,Periostin-CRE;NF2 fl/fl YAP fl/fl,animal_models,Experimental Usage,PUB36148553,RESd7bf5ba5,USE6022176e
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,Periostin-CRE;NF2 fl/fl TAZ fl/fl,animal_models,Experimental Usage,PUB36148553,RES59ac0b63,USE27d228d6
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,P0-CRE,animal_models,Experimental Usage,PUB36148553,RES6f70c029,USE6c016cdd
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,Postn-cre;Nf2f/f,animal_models,Experimental Usage,PUB32438526,RESe367efab,USEbc22d825
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,DhhCre;Nf1f/f;Luciferase,animal_models,Experimental Usage,PUB40723243,RES8b607c44,USE05a19618
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,Nf1+/− GFAP CKO,animal_models,Experimental Usage,PUB21963652,RESfd454e78,USEdb42f2d9
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,Tg(U6x:nf2a/b-4sgRNA),animal_models,Development,PUB39415595,RESc67bdf21,USE11028e7a
PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,NF1 R1947X minipig,animal_models,Development,PUB33978635,RES18e0d32c,USE6682d3f2
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,Nf1flox/mut;GFAP-Cre,animal_models,Experimental Usage,PUB24375753,RESb35d7371,USEb8e00198
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,TetOff-Osx-/-Nf1,animal_models,Experimental Usage,PUB25043591,RESb3e83b3e,USEd96ff346
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,Osx-/-Nf1flox/flox,animal_models,Experimental Usage,PUB25043591,RES75e5cd5b,USEbfc8af71
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,"Osx-tTA,tetO-cre;Nf1flox/flox",animal_models,Experimental Usage,PUB25043591,RES0fabb727,USE7576fece
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,Nf2 mice,animal_models,Experimental Usage,PUB24371224,RES4be903d5,USEb3e58d4d
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,Nf1+/-,animal_models,Experimental Usage,PUB23071067,RESd867fbf0,USE374d9f5b
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,Nf1+/-,animal_models,Experimental Usage,PUB16835260,RESd867fbf0,USE80620197
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,Nf2flox/flox,animal_models,Experimental Usage,PUB24817309,RES173e403d,USEdcdf8edb
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,hGFAP-cre,animal_models,Experimental Usage,PUB25535838,RESedb243f5,USE642ea09d
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,Math1-cre,animal_models,Experimental Usage,PUB25535838,RESc5783883,USE34e227f7
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,L7-cre,animal_models,Experimental Usage,PUB25535838,RESc188abac,USEa1b13642
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,Nf1 flox/flox,animal_models,Experimental Usage,PUB25535838,RESbf0146a3,USE0481f938
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,Nestin-creER,animal_models,Experimental Usage,PUB25535838,RES58594ca6,USE18334cd1
PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,Nf1 (+/-),animal_models,Experimental Usage,PUB26190969,RESd867fbf0,USE64125dd3
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,Nf1 flox/flox-;Postn-Cre,animal_models,Experimental Usage,PUB33658640,RES971399c4,USE32ac17a7
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,Nf1-Arf flox/flox ;Postn-Cre,animal_models,Experimental Usage,PUB33658640,RES70c2125d,USEd2b40d4b
PMID:22811580,10.1158/1078-0432.CCR-12-1072,Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.,,CNP-HRas12V,animal_models,Development,PUB22811580,RESbf0bcb00,USE3c7f34ed
PMID:32193437,10.1038/s41598-020-61251-4,Longitudinal phenotype development in a minipig model of neurofibromatosis type 1.,,NF1+/ex42del,animal_models,Experimental Usage,PUB32193437,RES7f9772df,USE521d9c0a
PMID:21980365,10.1371/journal.pone.0024917,The haploinsufficient hematopoietic microenvironment is critical to the pathological fracture repair in murine models of neurofibromatosis type 1.,,Nf1+/−,animal_models,Experimental Usage,PUB21980365,RESd867fbf0,USE5d9f4835
PMID:21980365,10.1371/journal.pone.0024917,The haploinsufficient hematopoietic microenvironment is critical to the pathological fracture repair in murine models of neurofibromatosis type 1.,,Nf1flox/flox,animal_models,Experimental Usage,PUB21980365,RESbf0146a3,USEed1ca567
PMID:21980365,10.1371/journal.pone.0024917,The haploinsufficient hematopoietic microenvironment is critical to the pathological fracture repair in murine models of neurofibromatosis type 1.,,PeriCre(+);Nf1(flox/-),animal_models,Experimental Usage,PUB21980365,RES7c49a647,USE7f296f86
PMID:21980365,10.1371/journal.pone.0024917,The haploinsufficient hematopoietic microenvironment is critical to the pathological fracture repair in murine models of neurofibromatosis type 1.,,Col2.3Cre(+);Nf1(flox/-),animal_models,Experimental Usage,PUB21980365,RES5881c141,USE88b74964
PMID:24997609,10.1038/nm.3583,"Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1.",,Nf1 flox/flox mice; α1(II) collagen-Cre,animal_models,Experimental Usage,PUB24997609,RESadd174db,USEe9c3c1be
PMID:24997609,10.1038/nm.3583,"Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1.",,Osx-cre; Nf1 flox/flox,animal_models,Experimental Usage,PUB24997609,RESfc07422a,USE2ae7e2ae
PMID:24997609,10.1038/nm.3583,"Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1.",,Nf1 flox/flox,animal_models,Experimental Usage,PUB24997609,RESbf0146a3,USE4a560284
PMID:37406085,10.1158/1078-0432.CCR-22-2854,Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma.,,Nf1flox/flox;PostnCre,animal_models,Experimental Usage,PUB37406085,RES971399c4,USE7724e1e1
PMID:21157378,10.1097/NEN.0b013e3182032d37,Neurofibromatosis-1 heterozygosity increases microglia in a spatially and temporally restricted pattern relevant to mouse optic glioma formation and growth.,,Nf1 flox/- ; GFAP-Cre,animal_models,Experimental Usage,PUB21157378,RES978912c9,USE1662fa73
PMID:21157378,10.1097/NEN.0b013e3182032d37,Neurofibromatosis-1 heterozygosity increases microglia in a spatially and temporally restricted pattern relevant to mouse optic glioma formation and growth.,,Nf1 +/- ;Cx3cr1+/GFP,animal_models,Experimental Usage,PUB21157378,RESc06d9b49,USE24d0fc2d
PMID:25877069,10.1007/s11626-015-9885-z,Establishment of immortalized murine mesothelial cells and a novel mesothelioma cell line.,,Nf2+/-,animal_models,Experimental Usage,PUB25877069,RES4be903d5,USEfe22d085
PMID:37817770,10.3389/fonc.2023.1253659,Single-cell RNA sequencing of neurofibromas reveals a tumor microenvironment favorable for neural regeneration and immune suppression in a neurofibromatosis type 1 porcine model.,,NF1 exon a31 excision,animal_models,Experimental Usage,PUB37817770,RES13dac434,USE58f55756
PMID:16524466,10.1186/1471-2202-7-22,Cognitive dysfunction in NF1 knock-out mice may result from altered vesicular trafficking of APP/DRD3 complex.,,Nf1tm1Fcr,animal_models,Experimental Usage,PUB16524466,RES87ed8d02,USE721d18ba
PMID:25433207,10.1016/j.ydbio.2014.11.017,Nf2-Yap signaling controls the expansion of DRG progenitors and glia during DRG development.,,Nf2 Flox/Flox,animal_models,Experimental Usage,PUB25433207,RES173e403d,USEa82295cf
PMID:36799629,10.1158/1078-0432.CCR-22-3722,MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors.,,C57BL6/J Nf1±; Trp53±cis,animal_models,Experimental Usage,PUB36799629,RES5610385e,USEefe5b463
PMID:19427294,10.1016/j.stem.2009.03.017,Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas.,,Nf1 flox/-,animal_models,Experimental Usage,PUB19427294,RESd390084f,USE5ac54368
PMID:23099891,10.1007/s00401-012-1056-7,Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition.,,Dhh-Cre; Nf1(flox/flox),animal_models,Experimental Usage,PUB23099891,RES02ec2a42,USE5a254492
PMID:19041782,10.1016/j.stem.2008.10.003,Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential.,,Nf1+/- C57Bl/6,animal_models,Experimental Usage,PUB19041782,RES6d726611,USE6d4b00d8
PMID:19041782,10.1016/j.stem.2008.10.003,Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential.,,Nf1 129X1/SvJ +/−,animal_models,Experimental Usage,PUB19041782,RES6737450f,USEe48981a3
PMID:19041782,10.1016/j.stem.2008.10.003,Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential.,,DhhCre;Nf1fl/fl,animal_models,Experimental Usage,PUB19041782,RES41704967,USEc4353b3a
PMID:38900740,10.1371/journal.pone.0301040,Revisiting the NPcis mouse model: A new tool to model plexiform neurofibroma.,,NPcis,animal_models,Experimental Usage,PUB38900740,RESf5e1c690,USE04dc2b3c
PMID:38900740,10.1371/journal.pone.0301040,Revisiting the NPcis mouse model: A new tool to model plexiform neurofibroma.,,Hoxb7-cre Nf1 f/f,animal_models,Experimental Usage,PUB38900740,RESf32a9519,USE7135d51d
PMID:37616542,10.1158/1535-7163.MCT-23-0258,"Pro-905, a Novel Purine Antimetabolite, Combines with Glutamine Amidotransferase Inhibition to Suppress Growth of Malignant Peripheral Nerve Sheath Tumor.",,B6;129S2-Trp53tm1Tyj Nf1tm1Tyj,animal_models,Experimental Usage,PUB37616542,RESf38e5471,USEacd6303b
PMID:19306381,10.1002/glia.20866,Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.,,P0-GGFβ3,animal_models,Experimental Usage,PUB19306381,RES1902f508,USE565485e6
PMID:41616055,10.1126/sciadv.ady8382,Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis.,,Nf2 flox/flox;Postn-Cre+,animal_models,Experimental Usage,PUB41616055,RESbc516f0e,USE8549b7d0
PMID:29590612,10.1016/j.celrep.2018.03.014,A Conserved Circadian Function for the Neurofibromatosis 1 Gene.,,P1 Nf1,animal_models,Experimental Usage,PUB29590612,RESfea23225,USEef1dcef1
PMID:29590612,10.1016/j.celrep.2018.03.014,A Conserved Circadian Function for the Neurofibromatosis 1 Gene.,,Nf1 flox/flox,animal_models,Experimental Usage,PUB29590612,RESbf0146a3,USE444edec6
PMID:17216419,10.1007/s10048-006-0078-5,Nf1 expression is dependent on strain background: implications for tumor suppressor haploinsufficiency studies.,,NPcis,animal_models,Experimental Usage,PUB17216419,RESf5e1c690,USE02cac169
PMID:17216419,10.1007/s10048-006-0078-5,Nf1 expression is dependent on strain background: implications for tumor suppressor haploinsufficiency studies.,,Nf1-/+;Trp53-/+cis,animal_models,Experimental Usage,PUB17216419,RESfd21ac68,USE926c145a
PMID:16314489,10.1242/dev.02162,Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation.,,Nf1flox/flox; hGFAP-cre+,animal_models,Experimental Usage,PUB16314489,RESd038a0d8,USE5c00cfaf
PMID:16314489,10.1242/dev.02162,Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation.,,Nf1flox/−; hGFAP-cre+,animal_models,Experimental Usage,PUB16314489,RESa3844810,USEd7d194cd
PMID:18671844,10.1186/1741-7015-6-21,Modelling neurofibromatosis type 1 tibial dysplasia and its treatment with lovastatin.,,Nf1Prx1,animal_models,Experimental Usage,PUB18671844,RESe475a58f,USEb6b53d9d
PMID:18671844,10.1186/1741-7015-6-21,Modelling neurofibromatosis type 1 tibial dysplasia and its treatment with lovastatin.,,Nf1flox,animal_models,Experimental Usage,PUB18671844,RESd390084f,USE96fc27ec
PMID:18984156,10.1016/j.cell.2008.08.041,Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow.,,Krox20;Nf1flox/flox,animal_models,Experimental Usage,PUB18984156,RESfcfb5e84,USE7c1558fb
PMID:18984156,10.1016/j.cell.2008.08.041,Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow.,,Krox20;Nf1flox/−,animal_models,Experimental Usage,PUB18984156,RES125ea802,USE375dce75
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,neurofibromin,antibodies,Experimental Usage,PUB38216123,RESb9e87b61,USE171f993c
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,neurofibromin,antibodies,Experimental Usage,PUB38216123,RESb9e87b61,USE171f993c
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,neurofibromin,antibodies,Experimental Usage,PUB38216123,RESb9e87b61,USE171f993c
PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,Merlin,antibodies,Experimental Usage,PUB24595234,RES1e67e0f9,USE77ea90f4
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,NF1,antibodies,Experimental Usage,PUB30479396,RESfb1ea3d8,USE52e6c914
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,NF1,antibodies,Experimental Usage,PUB30479396,RESfb1ea3d8,USE52e6c914
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,NF1GRP-D,antibodies,Experimental Usage,PUB19191334,REScb3fd620,USE44867ab4
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,Merlin,antibodies,Experimental Usage,PUB32457840,RES1e67e0f9,USEabd12987
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,NF2/merlin,antibodies,Experimental Usage,PUB33273014,RES2fa09c89,USE906a603d
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,NF1,antibodies,Experimental Usage,PUB41022755,RESfb1ea3d8,USEea408dc3
PMID:34945792,10.3390/jpm11121320,Restoration of Normal NF1 Function with Antisense Morpholino Treatment of Recurrent Pathogenic Patient-Specific Variant c.1466A>G; p.Y489C.,,NF1,antibodies,Experimental Usage,PUB34945792,RESfb1ea3d8,USE581fbf3c
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,NF1,antibodies,Experimental Usage,PUB39129390,RESfb1ea3d8,USE27bc2f28
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,Drosophila neurofibromin,antibodies,Experimental Usage,PUB39129390,RESe7ee1579,USE47d941ac
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,human neurofibromin,antibodies,Experimental Usage,PUB39129390,RESb1341551,USEc4962954
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,Merlin,antibodies,Experimental Usage,PUB28126595,RES1e67e0f9,USE4695cd3f
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,phospho-Merlin,antibodies,Experimental Usage,PUB28126595,RES870ee31a,USE2cfda85f
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,Merlin,antibodies,Experimental Usage,PUB29715273,RES1e67e0f9,USEd9dad85e
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,Merlin,antibodies,Experimental Usage,PUB29715273,RES1e67e0f9,USEd9dad85e
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,Merlin,antibodies,Experimental Usage,PUB29715273,RES1e67e0f9,USEd9dad85e
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,NF2,antibodies,Experimental Usage,PUB29715273,RESa1a9bc9f,USE6548be1b
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,phospho S518-Merlin,antibodies,Experimental Usage,PUB29715273,RESdd5ecbbb,USE6b25a06c
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,neurofibromin,antibodies,Experimental Usage,PUB39890807,RESb9e87b61,USE7f960dc6
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,neurofibromin,antibodies,Experimental Usage,PUB38481529,RESb9e87b61,USEe4d0ca74
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,neurofibromin/NF1,antibodies,Experimental Usage,PUB40590220,RES07ab6ac4,USE773836b5
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,neurofibromin/NF1,antibodies,Experimental Usage,PUB40590220,RES07ab6ac4,USE773836b5
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,neurofibromin/NF1,antibodies,Experimental Usage,PUB40590220,RES07ab6ac4,USE773836b5
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,neurofibromin,antibodies,Experimental Usage,PUB29438698,RESb9e87b61,USE9b01a8ed
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,merlin,antibodies,Experimental Usage,PUB20195187,RES1e67e0f9,USEa6ca15d8
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,merlin,antibodies,Experimental Usage,PUB20195187,RES1e67e0f9,USEa6ca15d8
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,merlin,antibodies,Experimental Usage,PUB30274821,RES1e67e0f9,USEc1218c99
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,neurofibromin,antibodies,Experimental Usage,PUB37446790,RESb9e87b61,USE9aa2af03
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,NF1,antibodies,Experimental Usage,PUB34011935,RESfb1ea3d8,USE28f1a1a7
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,neurofibromin 1,antibodies,Experimental Usage,PUB41036607,RESbd6927a8,USE99d94341
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,NF2,antibodies,Experimental Usage,PUB26219339,RESa1a9bc9f,USE068da979
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,NF1,antibodies,Experimental Usage,PUB28166733,RESfb1ea3d8,USE77f7467e
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,SUZ12,antibodies,Experimental Usage,PUB28166733,RES61579cf6,USE33b1d526
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,Merlin,antibodies,Experimental Usage,PUB21072183,RES1e67e0f9,USEb43a3b69
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,NF1,antibodies,Experimental Usage,PUB38714355,RESfb1ea3d8,USE8cc8ed6b
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,NF1,antibodies,Experimental Usage,PUB39472976,RESfb1ea3d8,USE7ac759fe
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,NF1,antibodies,Experimental Usage,PUB39472976,RESfb1ea3d8,USE7ac759fe
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,NF1,antibodies,Experimental Usage,PUB41564118,RESfb1ea3d8,USEce0b88b7
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,NF2/Merlin,antibodies,Experimental Usage,PUB38216572,RES2fa09c89,USE1a29183e
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,S518-Merlin,antibodies,Experimental Usage,PUB25043298,RESacca97fb,USE514b1949
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,S518-Merlin,antibodies,Experimental Usage,PUB25043298,RESacca97fb,USE514b1949
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,merlin,antibodies,Experimental Usage,PUB39415595,RES1e67e0f9,USEd3299e1e
PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,NF2/merlin,antibodies,Experimental Usage,PUB19144871,RES2fa09c89,USEc81bac00
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,neurofibromin,antibodies,Experimental Usage,PUB36241865,RESb9e87b61,USEb33d1936
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,Nf1,antibodies,Experimental Usage,PUB25535838,RESfb1ea3d8,USE7e6e647b
PMID:24786638,10.1016/j.ygyno.2014.04.044,Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.,,Merlin,antibodies,Experimental Usage,PUB24786638,RES1e67e0f9,USE138568b4
PMID:24786638,10.1016/j.ygyno.2014.04.044,Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.,,NF2,antibodies,Experimental Usage,PUB24786638,RESa1a9bc9f,USEb46deff9
PMID:39016685,10.1242/jcs.262343,Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss.,,NF1,antibodies,Experimental Usage,PUB39016685,RESfb1ea3d8,USEb011398a
PMID:33574490,10.1038/s41598-021-83152-w,Using antisense oligonucleotides for the physiological modulation of the alternative splicing of NF1 exon 23a during PC12 neuronal differentiation.,,NF1,antibodies,Experimental Usage,PUB33574490,RESfb1ea3d8,USE6c90d084
PMID:33574490,10.1038/s41598-021-83152-w,Using antisense oligonucleotides for the physiological modulation of the alternative splicing of NF1 exon 23a during PC12 neuronal differentiation.,,NF1,antibodies,Experimental Usage,PUB33574490,RESfb1ea3d8,USE6c90d084
PMID:25433207,10.1016/j.ydbio.2014.11.017,Nf2-Yap signaling controls the expansion of DRG progenitors and glia during DRG development.,,Nf2,antibodies,Experimental Usage,PUB25433207,RESa1a9bc9f,USE2e4b27ab
PMID:38900740,10.1371/journal.pone.0301040,Revisiting the NPcis mouse model: A new tool to model plexiform neurofibroma.,,Nf1,antibodies,Experimental Usage,PUB38900740,RESfb1ea3d8,USEcdc1b001
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,NPcis cell line,cell_lines,Experimental Usage,PUB32642734,RES63492a0a,USE20dce609
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,BJFF.6,cell_lines,Experimental Usage,PUB35589737,RES46b2e4c2,USE0467cf9f
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,Normal human Schwann cells (Sciencell),cell_lines,Experimental Usage,PUB35589737,RES2b525570,USE4d3d7f6b
PMID:12057013,10.1186/1471-2164-3-13,Complex splicing pattern generates great diversity in human NF1 transcripts.,,TOP-10F' cells,cell_lines,Experimental Usage,PUB12057013,RES64383697,USE8e881073
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,MCF7,cell_lines,Experimental Usage,PUB38216123,RES1945f01f,USEa95b1f36
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,Nf1 flox/flox calvaria osteoblasts,cell_lines,Experimental Usage,PUB20200958,RESd9a729dd,USEbf743cfb
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,DH10Bac cells,cell_lines,Experimental Usage,PUB31836666,RESdd4069b7,USE511ac279
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,BL21(DE3),cell_lines,Experimental Usage,PUB31836666,RES723c52d9,USE25fe230e
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,Sf9 cells,cell_lines,Experimental Usage,PUB31836666,RES649a81c4,USE28a9212b
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,Tni-FNL cells,cell_lines,Experimental Usage,PUB31836666,RESfe968e38,USEfdb8d8d4
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,NF1-null HEK293T cell line,cell_lines,Development,PUB31836666,REScf18c3c5,USEb518f376
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,HEK293T,cell_lines,Experimental Usage,PUB31836666,RES7f062621,USE838bf5c6
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,S462TY,cell_lines,Experimental Usage,PUB38201517,RESba144dfb,USE0664214a
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,iSC,cell_lines,Experimental Usage,PUB38201517,RES0f0c862a,USE003e5473
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,A549,cell_lines,Experimental Usage,PUB38201517,RESd602b122,USE43e178d0
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,ST88-14,cell_lines,Experimental Usage,PUB38201517,RES8c79577c,USEd234a882
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,MCF10A,cell_lines,Experimental Usage,PUB38201517,RES13ccb15b,USE12937665
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,murine NF2 −/− Schwann cell line,cell_lines,Experimental Usage,PUB30617350,RESd6bdbe98,USEf3b3f0a3
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,HEI-193,cell_lines,Experimental Usage,PUB30617350,RES83633cde,USE75d77cb5
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,ipNF05.5 (mixed clone),cell_lines,Experimental Usage,PUB35741605,RES27a80654,USE46cc18b1
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,ipNF05.5 (single clone),cell_lines,Experimental Usage,PUB35741605,RESc8a1bf77,USEf9a2f559
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,ipNF95.11bC,cell_lines,Experimental Usage,PUB35741605,RES8555ee4e,USEe34dedf9
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,ipNF95.6,cell_lines,Experimental Usage,PUB35741605,RES53c1db9a,USEba37d8d0
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,ipnNF95.11c,cell_lines,Experimental Usage,PUB35741605,RESd7276863,USE99593aa7
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,HEK 293T,cell_lines,Experimental Usage,PUB40225167,RES7f062621,USEa763f5b8
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,COS-7,cell_lines,Experimental Usage,PUB40225167,RESabb7add4,USE88d95712
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,Nf1-/- mouse embryo fibroblasts,cell_lines,Experimental Usage,PUB21199799,RESabd0cc70,USE4e3402ae
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,Nf1+/- mouse embryo fibroblasts,cell_lines,Experimental Usage,PUB21199799,RESabd0cc70,USE7047fd93
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,T265-2c,cell_lines,Experimental Usage,PUB24824755,RES7d7c375d,USEb4c288c9
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,ST88-14,cell_lines,Experimental Usage,PUB24824755,RES8c79577c,USE0bdd10af
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,90-8,cell_lines,Experimental Usage,PUB24824755,RES4d55b268,USE00240952
PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,NF96.2,cell_lines,Experimental Usage,PUB24040940,RES68239221,USEdc045858
PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,NF02.2,cell_lines,Experimental Usage,PUB24040940,RESc0c71d85,USEac0b96f6
PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,NF94.3,cell_lines,Experimental Usage,PUB24040940,RESae0432c8,USEf7088862
PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and,,LLC-PK1 ATCC CL-101,cell_lines,Experimental Usage,PUB34630515,RES98351e60,USE07500ce2
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,MIAPaCa-2,cell_lines,Experimental Usage,PUB32457840,RES3224a315,USEc923b986
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,Panc-1,cell_lines,Experimental Usage,PUB32457840,RES928f1713,USE011ded68
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,BxPC-3,cell_lines,Experimental Usage,PUB32457840,RESd23e6c85,USEc91f241e
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,AsPC-1,cell_lines,Experimental Usage,PUB32457840,RES660e82ea,USE26a6d7b7
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,HPDE H6c7,cell_lines,Experimental Usage,PUB32457840,RES00c86d4a,USE207b3c73
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,Ben-Men-1,cell_lines,Experimental Usage,PUB33273014,RES8ba7d57b,USE5c04425f
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,AC-CRISPR,cell_lines,Experimental Usage,PUB33273014,RESc40180a9,USEdd7577b2
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,MN1-LF,cell_lines,Experimental Usage,PUB33273014,RESd4d873f7,USE4e7acdc4
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,H358 cells,cell_lines,Experimental Usage,PUB38502231,RES6448cbce,USEf2f11513
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,S462 cells,cell_lines,Experimental Usage,PUB38502231,RES7787dd40,USE294e3560
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,cis MPNST cell line,cell_lines,Experimental Usage,PUB38502231,RESbf9e0bf2,USE234b716d
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,HTS-Luc MPNST cell line,cell_lines,Experimental Usage,PUB38502231,RES9709e143,USEec716322
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,pNF9511bc,cell_lines,Experimental Usage,PUB41022755,RESd2d7bbb3,USEe28f57d8
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,ipNF03.3,cell_lines,Experimental Usage,PUB41022755,RES4029030f,USE53f3bfaf
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,ipn023λ,cell_lines,Experimental Usage,PUB41022755,RES22f213dc,USE2373d42f
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,ST88-14,cell_lines,Experimental Usage,PUB41022755,RES8c79577c,USE8f8da322
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,S462,cell_lines,Experimental Usage,PUB41022755,RES7787dd40,USE39dee71f
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,RHT92,cell_lines,Experimental Usage,PUB41022755,RESbf7021d2,USEcca70cd9
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,LN229,cell_lines,Experimental Usage,PUB41022755,RESec88ccdf,USE62471023
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,2V6.11,cell_lines,Experimental Usage,PUB41022755,RES0162cd28,USEeb534f55
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,FiPS,cell_lines,Experimental Usage,PUB41022755,RESd0d2a3a9,USE5dac34d6
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,"NF1−/−−/− edited FiPS Ctrl1-SV4F-7, D12",cell_lines,Experimental Usage,PUB41022755,RESdc14408d,USEc41e640f
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,3PNF_SiPSsv_MM_11,cell_lines,Experimental Usage,PUB41022755,RES63dfec23,USEa5f0cfc5
PMID:34945792,10.3390/jpm11121320,Restoration of Normal NF1 Function with Antisense Morpholino Treatment of Recurrent Pathogenic Patient-Specific Variant c.1466A>G; p.Y489C.,,PGP1,cell_lines,Experimental Usage,PUB34945792,RES2a368812,USEb15b8a7e
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,ST88-14,cell_lines,Experimental Usage,PUB39269317,RES8c79577c,USE9627a06d
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,M724,cell_lines,Experimental Usage,PUB39269317,RES0b303b9d,USE89ad1748
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,SNF96.2,cell_lines,Experimental Usage,PUB39269317,RES65ffa5bf,USE6a7edd80
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,HEK-293T,cell_lines,Experimental Usage,PUB39269317,RES7f062621,USEebeb69a4
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,M1,cell_lines,Experimental Usage,PUB39269317,RESa3b8883e,USE2d41a72b
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,M3,cell_lines,Experimental Usage,PUB39269317,RESdc69ceb0,USE773903ae
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,M4,cell_lines,Experimental Usage,PUB39269317,RESd9806b0b,USE7cff0a8f
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,M5,cell_lines,Experimental Usage,PUB39269317,RESa330fc30,USE81ca75b2
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,M6,cell_lines,Experimental Usage,PUB39269317,RES15880533,USEa9533c45
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,Drosophila Schneider (S2R+) cells,cell_lines,Experimental Usage,PUB39129390,RES65662a6d,USE20b1e11a
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,dNF1‐KO,cell_lines,Development,PUB39129390,REScd43134d,USEa37cc84c
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,hTERT ipn02.3 2λ CRL‐3392,cell_lines,Experimental Usage,PUB39129390,RES2fe12b13,USE235c3484
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,"ipnNF95.11C (hTERT NF1 ipnNF95.11c, RRID: CVCL_UI69)",cell_lines,Experimental Usage,PUB39129390,RESd7276863,USE00a2f17d
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,"ipNF95.11b 'C' (hTERT NF1 ipNF95.11b C, RRID: CVCL_UI67)",cell_lines,Experimental Usage,PUB39129390,RES8555ee4e,USE33f9d9a2
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,"ipnNF09.4 (hTERT NF1 ipnNF09.4, RRID: CVCL_UI73)",cell_lines,Experimental Usage,PUB39129390,RES5e08b0cc,USEf920c01b
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,"ipNF05.5 (hTERT NF1 ipNF05.5, RRID: CVCL_UI71)",cell_lines,Experimental Usage,PUB39129390,RES5de742ed,USE7fb24820
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,ST88‐14 (RRID: CVCL_8916),cell_lines,Experimental Usage,PUB39129390,RES8c79577c,USEa4efed84
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,U2OS,cell_lines,Experimental Usage,PUB30531922,RES0242f8da,USE9526e844
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,HEK293,cell_lines,Experimental Usage,PUB30531922,RESbaa9fdad,USE1f0dd3dd
PMID:21111000,10.1016/j.jneumeth.2010.10.021,A novel imaging-compatible sciatic nerve schwannoma model.,,HEI-193,cell_lines,Experimental Usage,PUB21111000,RES83633cde,USEed83dfbc
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,Human meningeal cells (HMC),cell_lines,Experimental Usage,PUB28126595,RES35bbc5c9,USE569c32ef
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,Ben-Men-1 cells,cell_lines,Experimental Usage,PUB28126595,RES8ba7d57b,USE4c4eade3
PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,lymphoblastoid cell lines,cell_lines,Experimental Usage,PUB25329635,RESb9449add,USE3012b2fe
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,iPNF95.6,cell_lines,Experimental Usage,PUB33442015,RES53c1db9a,USE2504050d
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,OLN93 mouse oligodendrocyte cell line,cell_lines,Experimental Usage,PUB29715273,RES33b4d8cc,USEe55cf007
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,SC4-immortalized Nf2-/- primary Schwann cells,cell_lines,Experimental Usage,PUB29715273,RES4bb1d196,USE4cc49875
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,RT4-D6PT2 schwannoma cell line,cell_lines,Experimental Usage,PUB29715273,RESc23eadf1,USE8ab97592
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,TC620 human oligodendroglioma cell line,cell_lines,Experimental Usage,PUB29715273,RES6b2e8a99,USE04b61aa3
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,Normal human Schwann cells (NHSC),cell_lines,Experimental Usage,PUB24509877,RESb2bfc67f,USEe956f922
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,MPNST cell lines,cell_lines,Experimental Usage,PUB24509877,RES8bfa4d28,USE8d241e44
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,MPNST 88-14 cells,cell_lines,Experimental Usage,PUB24509877,RES8fea907c,USE17f07bde
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,MPNST S462-TY cells,cell_lines,Experimental Usage,PUB24509877,RES6703798b,USEe282f21f
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,S462 cell line,cell_lines,Experimental Usage,PUB23328114,RES7787dd40,USEc6803a5f
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,2884 cell line,cell_lines,Experimental Usage,PUB23328114,RES08493b1a,USEcfab1094
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,2885 cell line,cell_lines,Experimental Usage,PUB23328114,RES9228949e,USE8aa8f120
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,hTERT NF1 ipn02.3 2λ,cell_lines,Experimental Usage,PUB36322658,RESa4c9d0d2,USE139dc597
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,ipn95.11bC,cell_lines,Experimental Usage,PUB36322658,RESc11f75a8,USEc6d3f939
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,sNF96.2,cell_lines,Experimental Usage,PUB36322658,RES65ffa5bf,USEf51b45a1
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,MPNST642,cell_lines,Experimental Usage,PUB36322658,RESfc99283a,USEcbc852ac
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,T265,cell_lines,Experimental Usage,PUB36322658,RES46d7227b,USE15fd382a
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,STS26T,cell_lines,Experimental Usage,PUB36322658,RES74567322,USE947b7bc1
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,ipn97.4 immortalized human Schwann cells,cell_lines,Experimental Usage,PUB39890807,RES5718db6a,USE21b47247
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,Schwann cells,cell_lines,Experimental Usage,PUB37520682,RES4bc847e6,USEef93c1c4
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,optic glioma cells,cell_lines,Experimental Usage,PUB34040258,RES5ca9707b,USE6f371e63
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,HSC1λ,cell_lines,Experimental Usage,PUB37164978,RESaed6fdb0,USE1c445731
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,ipNF06.2A,cell_lines,Experimental Usage,PUB37164978,RES2d65bb8e,USEf1e44511
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,STS-26T,cell_lines,Experimental Usage,PUB37164978,RES74567322,USE021122eb
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,S462,cell_lines,Experimental Usage,PUB37164978,RES7787dd40,USEdae2b5ce
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,S462TY,cell_lines,Experimental Usage,PUB37164978,RESba144dfb,USEcca5d71f
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,T265,cell_lines,Experimental Usage,PUB37164978,RES46d7227b,USE57163ac3
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,NF1-1 hiPSC line,cell_lines,Experimental Usage,PUB38481529,REScb018edb,USE68abe399
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,NF1-2 hiPSC line,cell_lines,Experimental Usage,PUB38481529,RES44e8d8f6,USE32eaea33
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,WT-1 hiPSC line,cell_lines,Experimental Usage,PUB38481529,RES71ae386c,USE9d1a4c8f
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,WT-2 hiPSC line,cell_lines,Experimental Usage,PUB38481529,RES637f1fbc,USEae0b4b7b
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,HEK293T cells,cell_lines,Experimental Usage,PUB40590220,RES7f062621,USEb2d37017
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,HeLa cells,cell_lines,Experimental Usage,PUB40590220,RES1de4e591,USEa24a3142
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,LUVA cells,cell_lines,Experimental Usage,PUB40590220,RESbb2011d5,USE8538e7f5
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,HEI-193,cell_lines,Experimental Usage,PUB38216587,RES83633cde,USE95d65e76
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,"Human Schwann Cells (HSC, ScienCell Research Laboratories #1700)",cell_lines,Experimental Usage,PUB38216587,RES8ff373eb,USE911fa3f2
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,"Mouse Schwann Cells (MSC, ScienCell Research Laboratories #M1700-57)",cell_lines,Experimental Usage,PUB38216587,RESeb9e3bd3,USE7b997fb1
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,HEK-293T,cell_lines,Experimental Usage,PUB38216587,RES7f062621,USE34ef33da
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,NF37,cell_lines,Experimental Usage,PUB29941005,RESbaf0c6ad,USE7b71047b
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,NF87,cell_lines,Experimental Usage,PUB29941005,RES4f830669,USEac4cb954
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,CT10,cell_lines,Experimental Usage,PUB29941005,RES0bb17402,USEc2ecf0c2
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,CT11,cell_lines,Experimental Usage,PUB29941005,RES2566bbac,USE2bcfee78
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,CT12,cell_lines,Experimental Usage,PUB29941005,RESe416a28a,USE2e862478
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,SNF02.2,cell_lines,Experimental Usage,PUB29438698,RES359bb0bd,USE62c2928f
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,SNF96.2,cell_lines,Experimental Usage,PUB29438698,RES65ffa5bf,USE1b590039
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,TM-31,cell_lines,Experimental Usage,PUB36730269,RES7b299c69,USE646ae8f4
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,LN319,cell_lines,Experimental Usage,PUB36730269,RESecb75ef8,USE23f66ed2
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,17,cell_lines,Experimental Usage,PUB36730269,RESa28a03a6,USE44cab8cc
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,5653,cell_lines,Experimental Usage,PUB36730269,RESa015d578,USEefb0eeb6
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,5746,cell_lines,Experimental Usage,PUB36730269,RESe4bdb201,USE31ccf646
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,"Human Schwann cells (HSC; ScienCell, Carlsbad, CA)",cell_lines,Experimental Usage,PUB20195187,RES2c34b788,USEb734a327
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,MPNST,cell_lines,Experimental Usage,PUB18413802,RES8bfa4d28,USE1d43fbc4
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,ST8814,cell_lines,Experimental Usage,PUB18413802,RES8c79577c,USE1c536cc9
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,LS141,cell_lines,Experimental Usage,PUB18413802,RES310ed0e3,USE16100690
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,DDLS,cell_lines,Experimental Usage,PUB18413802,RES4ea34695,USEa5283281
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,Human Schwann cells (HSCs),cell_lines,Experimental Usage,PUB30274821,RESa6f1e455,USE4e5d18e2
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,RT4-D6P2T schwannoma cells,cell_lines,Experimental Usage,PUB30274821,RES8053683d,USE4ad7d94d
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,HEI-193,cell_lines,Experimental Usage,PUB30274821,RES83633cde,USEa63e8b96
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,HEK 293T cell line,cell_lines,Experimental Usage,PUB20554030,RES7f062621,USE549ed8e1
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,LN428 human glioblastoma multiforme (GBM) cell line,cell_lines,Experimental Usage,PUB20554030,RES6e47acf7,USE333c55cd
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,C2C12,cell_lines,Experimental Usage,PUB37446790,RES27fb92bc,USEe50c3d4f
PMID:40862755,10.3390/cells14161276,Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.,,ipNF95.11b C,cell_lines,Experimental Usage,PUB40862755,RES8555ee4e,USEb40ae460
PMID:40862755,10.3390/cells14161276,Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.,,ipNF05.5,cell_lines,Experimental Usage,PUB40862755,RES5de742ed,USE551cf5f1
PMID:28831766,10.1007/s12104-017-9768-1,NMR resonance assignments of the EVH1 domain of neurofibromin's recruitment factor Spred1.,,BL21(DE3) Star,cell_lines,Experimental Usage,PUB28831766,RES30a714b9,USEe849debd
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,NF1-null 293T cells,cell_lines,Experimental Usage,PUB36689660,REScc45049c,USE6a479bca
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,ipNF95.11b C,cell_lines,Experimental Usage,PUB36689660,RES8555ee4e,USE1a67a3a1
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,JH-2-002,cell_lines,Experimental Usage,PUB38000020,RES06bbbd46,USE686747a1
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,JH-2-031,cell_lines,Experimental Usage,PUB38000020,RES748525c7,USE150ad7b3
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,JH-2-079c,cell_lines,Experimental Usage,PUB38000020,RES24aca845,USE882ad06d
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,JH-2-103,cell_lines,Experimental Usage,PUB38000020,RES76c34922,USEd32b33df
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,iHSCs,cell_lines,Experimental Usage,PUB23685747,RES9da57d39,USE04abde88
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,ST88-14,cell_lines,Experimental Usage,PUB23685747,RES8c79577c,USEa6bebb60
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,STS26T,cell_lines,Experimental Usage,PUB23685747,RES74567322,USE80b4cc66
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,S462,cell_lines,Experimental Usage,PUB23685747,RES7787dd40,USE08b2ac06
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,S462-TY,cell_lines,Experimental Usage,PUB23685747,RESba144dfb,USEad1e9ae4
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,T265,cell_lines,Experimental Usage,PUB23685747,RES46d7227b,USE7cfa69c0
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,K562,cell_lines,Experimental Usage,PUB23685747,RESfdd6b370,USE93054760
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,icNF 97.2a,cell_lines,Experimental Usage,PUB38907342,RES6156e612,USEccb4c8f2
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,icNF 97.2b,cell_lines,Experimental Usage,PUB38907342,RESe3697125,USE51263564
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,icNF 98.4d,cell_lines,Experimental Usage,PUB38907342,RES0583d402,USE9f2063a3
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,293T cells,cell_lines,Experimental Usage,PUB40025578,RES63f2af1e,USE2be6948a
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,sNF96.2,cell_lines,Experimental Usage,PUB40025578,RES65ffa5bf,USEea3c9d42
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,HFFs,cell_lines,Experimental Usage,PUB40025578,RESd6afe7f8,USE5a51b9a4
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,NCI-H266,cell_lines,Experimental Usage,PUB40025578,RES32251ebd,USE01a6d9f6
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,K562,cell_lines,Experimental Usage,PUB40025578,RESfdd6b370,USEdf97de3e
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,Neurofibromatosis 1 fibroblasts,cell_lines,Experimental Usage,PUB34011935,RES015a8eda,USE6992c8e1
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,iHSCs,cell_lines,Experimental Usage,PUB41036607,RES9da57d39,USE5d031e15
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,S462-TY,cell_lines,Experimental Usage,PUB41036607,RESba144dfb,USEb43637cd
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,ST88-14,cell_lines,Experimental Usage,PUB41036607,RES8c79577c,USE70d0a051
PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,S462,cell_lines,Experimental Usage,PUB30055648,RES7787dd40,USE31d8e2d7
PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,T265,cell_lines,Experimental Usage,PUB30055648,RES46d7227b,USE28f0ccda
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,MPNST-SP-01,cell_lines,Experimental Usage,PUB35511749,RESf6ce18b7,USEb3b752a7
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,MPNST-NF1-08,cell_lines,Experimental Usage,PUB35511749,RESebfbb29f,USE4257d43b
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,MPNST-NF1-9,cell_lines,Experimental Usage,PUB35511749,RES62b59d33,USE3218cb28
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,STS-26T,cell_lines,Experimental Usage,PUB35511749,RES74567322,USE12056e6c
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,HS-PSS,cell_lines,Experimental Usage,PUB35511749,RESb82893e4,USEcbc6e056
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,HS-sch2,cell_lines,Experimental Usage,PUB35511749,RES871bb6fa,USE3c19830f
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,S462,cell_lines,Experimental Usage,PUB35511749,RES7787dd40,USEa848cc54
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,sNF96.2,cell_lines,Experimental Usage,PUB35511749,RES65ffa5bf,USE77fb8fce
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,Human Foreskin Fibroblast (HFF),cell_lines,Experimental Usage,PUB35511749,RES94d99650,USE41e236ae
PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,ipNF95.11b C,cell_lines,Experimental Usage,PUB39061138,RES8555ee4e,USE4269edcd
PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,ipNF95.11b C-RFP,cell_lines,Experimental Usage,PUB39061138,RESdf9174e6,USEa2f16f1d
PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,ipNF 05.5,cell_lines,Experimental Usage,PUB39061138,RES5de742ed,USE0f151a59
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,Ben-Men-1,cell_lines,Experimental Usage,PUB26219339,RES8ba7d57b,USEdf26db02
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,AC007-hTERT,cell_lines,Experimental Usage,PUB26219339,RESca37f0db,USE31cc8ad8
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,AC028,cell_lines,Experimental Usage,PUB26219339,RESeae42705,USE2927d574
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,293T,cell_lines,Experimental Usage,PUB26219339,RES63f2af1e,USEfa97c550
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,U87-MG,cell_lines,Experimental Usage,PUB28166733,RES02cd4945,USE90d9923f
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,HEK293T,cell_lines,Experimental Usage,PUB28166733,RES7f062621,USE87fe14f6
PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,,Meso-33,cell_lines,Experimental Usage,PUB25026211,RES7ec195a8,USE1414fbea
PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,,FC-1801,cell_lines,Experimental Usage,PUB25026211,RESba34146c,USE54c80388
PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,,293T,cell_lines,Experimental Usage,PUB25026211,RES63f2af1e,USE6577e563
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,NIH-3T3,cell_lines,Experimental Usage,PUB21072183,RES331e6cdf,USEe191390a
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,φNX packaging cell line,cell_lines,Experimental Usage,PUB21072183,RES27693bb3,USE1730448d
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,H1838,cell_lines,Experimental Usage,PUB33032988,RESc7b181eb,USE47348435
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,WM3918,cell_lines,Experimental Usage,PUB33032988,RES2a6648a2,USE95cf342e
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,M308,cell_lines,Experimental Usage,PUB33032988,RESa889216f,USE53abb4be
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,STS26T,cell_lines,Experimental Usage,PUB33032988,RES74567322,USEcf1686c2
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,ST8814,cell_lines,Experimental Usage,PUB33032988,RES8c79577c,USE766e9d93
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,NF90.8,cell_lines,Experimental Usage,PUB33032988,RES7d84433c,USE18ece940
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,NF94.3,cell_lines,Experimental Usage,PUB33032988,RESae0432c8,USEe2a11a99
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,NF96.2,cell_lines,Experimental Usage,PUB33032988,RES68239221,USEaf462a2a
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,NF10.1,cell_lines,Experimental Usage,PUB33032988,RES8cd5f20e,USE04c1b992
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,NF11.1,cell_lines,Experimental Usage,PUB33032988,RES437abbbb,USEe1b86666
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,K4622 grade II glioma cell line,cell_lines,Experimental Usage,PUB21216928,RESdb3ab40e,USE4cd892e2
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,HSR-GBM1,cell_lines,Experimental Usage,PUB38714355,RES0e69a08f,USE95898ca0
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,JHH-520,cell_lines,Experimental Usage,PUB38714355,RES7d16532b,USE7c787840
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,JHU-0879,cell_lines,Experimental Usage,PUB38714355,RES7cfe241c,USEbdec9c44
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,JHU-1016B,cell_lines,Experimental Usage,PUB38714355,RESd39ec166,USE26779c07
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,JHH-136,cell_lines,Experimental Usage,PUB38714355,RESe586e098,USE300ed0ca
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,B76,cell_lines,Experimental Usage,PUB38714355,RES7ba5993a,USE0a1bd05a
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,NGT-41,cell_lines,Experimental Usage,PUB38714355,RES8d501cc9,USEa0ec475e
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,NMCG-1,cell_lines,Experimental Usage,PUB38714355,RES240e5436,USE4c853b69
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,DBTRG,cell_lines,Experimental Usage,PUB38714355,RES25623437,USE1006d2f9
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,LN229,cell_lines,Experimental Usage,PUB38714355,RESec88ccdf,USEc6d63423
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,T98G,cell_lines,Experimental Usage,PUB38714355,RESd8d494a3,USE025ebefd
PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,PNF-derived Schwann cells,cell_lines,Experimental Usage,PUB25340526,RES828ab613,USE7366790e
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,JHH-520 cell line,cell_lines,Experimental Usage,PUB39472976,RES7d16532b,USE7d37126b
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,GBM1 cell line,cell_lines,Experimental Usage,PUB39472976,RES9927ef7e,USE31882738
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,JHH-0879 cell line,cell_lines,Experimental Usage,PUB39472976,RESbd60dbd9,USEc07c044b
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,ST88-14,cell_lines,Experimental Usage,PUB20049725,RES8c79577c,USE98db8b27
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,STS26T,cell_lines,Experimental Usage,PUB20049725,RES74567322,USE20445d92
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,S520,cell_lines,Experimental Usage,PUB20049725,RESeba89533,USEf98f868e
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,S462,cell_lines,Experimental Usage,PUB20049725,RES7787dd40,USE897deba8
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,88-3,cell_lines,Experimental Usage,PUB20049725,RES82831da4,USE9bca7ecf
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,90-8,cell_lines,Experimental Usage,PUB20049725,RES4d55b268,USE5650a950
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,YST1,cell_lines,Experimental Usage,PUB20049725,RESc41540f6,USEf5d1853f
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,icNF97.2a,cell_lines,Development,PUB41564118,RES6156e612,USEc7344a27
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,icNF97.2b,cell_lines,Development,PUB41564118,RESe3697125,USE5ddfe318
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,icNF98.4c,cell_lines,Development,PUB41564118,RES1f1514dd,USE388aeb38
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,icNF98.4d,cell_lines,Development,PUB41564118,RES0583d402,USEb0a15d05
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,icNF00.10a,cell_lines,Development,PUB41564118,RES42459202,USEae91ad03
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,icNF04.9a,cell_lines,Development,PUB41564118,RES458b9b4f,USE2852c773
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,i28cNF,cell_lines,Development,PUB41564118,RES0be2e415,USE6ec36049
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,i18cNF,cell_lines,Development,PUB41564118,RESa3568ca9,USE85979a13
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,i21cNF,cell_lines,Development,PUB41564118,RESbcad377e,USE7574f924
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,S462,cell_lines,Experimental Usage,PUB32642733,RES7787dd40,USEb3528801
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,ST88-14,cell_lines,Experimental Usage,PUB32642733,RES8c79577c,USE884cb37a
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,sNF96.2,cell_lines,Experimental Usage,PUB32642733,RES65ffa5bf,USEcca63da4
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,90-8,cell_lines,Experimental Usage,PUB32642733,RES4d55b268,USE422b67c2
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,STS-26T,cell_lines,Experimental Usage,PUB32642733,RES74567322,USE263f95ce
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,HS-Sch-2,cell_lines,Experimental Usage,PUB32642733,RES871bb6fa,USE2ffb6627
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,CCD-1112Sk,cell_lines,Experimental Usage,PUB32642733,RES1aa9a303,USE1993ad81
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,Rosetta2(DE3) competent cells,cell_lines,Experimental Usage,PUB24882693,RES40c42020,USE43bbe635
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,STS26T,cell_lines,Experimental Usage,PUB18483311,RES74567322,USEf99dec4d
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,ST8814,cell_lines,Experimental Usage,PUB18483311,RES8c79577c,USE0e140f87
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,ST88-3,cell_lines,Experimental Usage,PUB18483311,RES8fd7beb2,USE3fb648e9
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,S462,cell_lines,Experimental Usage,PUB18483311,RES7787dd40,USE93a65b17
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,T265p21,cell_lines,Experimental Usage,PUB18483311,REScea4eddb,USE5f17dcd4
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,S520,cell_lines,Experimental Usage,PUB18483311,RESeba89533,USE94840297
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,90-8,cell_lines,Experimental Usage,PUB18483311,RES4d55b268,USE335bca3b
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,YST1,cell_lines,Experimental Usage,PUB18483311,RESc41540f6,USEfefa2904
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,DS-red STS26T cell line,cell_lines,Experimental Usage,PUB18483311,RESe2bfa3a9,USEd939e90a
PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,hTERT ipNF05.5,cell_lines,Experimental Usage,PUB37140985,RES487eca0a,USE7bcbf489
PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,hTERT ipn02.3 2λ,cell_lines,Experimental Usage,PUB37140985,RESe9e677f7,USE680985f7
PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,E13.5 DRG neurosphere cells,cell_lines,Experimental Usage,PUB37140985,RES8e44a7c5,USEd916fe40
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,Daoy,cell_lines,Experimental Usage,PUB20551058,RES70f6328b,USEf0b95072
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,NF1-/- iPSC-derived neural crest cells,cell_lines,Experimental Usage,PUB38175707,RESc5815f89,USEdd0eb8d3
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,JH-2-002 cell line,cell_lines,Experimental Usage,PUB38127282,RES06bbbd46,USEbb856476
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,JH-2-103 cell line,cell_lines,Experimental Usage,PUB38127282,RES76c34922,USE021cee60
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,ST-8814 cell line,cell_lines,Experimental Usage,PUB38127282,RES8c79577c,USE51f3f405
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,S462 cell line,cell_lines,Experimental Usage,PUB38127282,RES7787dd40,USEba90a05f
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,hTERT ipn02.3 2λ cell line,cell_lines,Experimental Usage,PUB38127282,RESe9e677f7,USEb21794ef
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,hTERT NF1 ipNF95.6 cell line,cell_lines,Experimental Usage,PUB38127282,RES05f18fad,USE6380c3f3
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,ipnNF95.11C,cell_lines,Experimental Usage,PUB38136356,RESd7276863,USE3cdd9e70
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,ipNF05.5-MX,cell_lines,Experimental Usage,PUB38136356,RES4619f98d,USE2aaa2454
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,ipNF06.2A,cell_lines,Experimental Usage,PUB38136356,RES2d65bb8e,USE6f0765c7
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,ipNF95.11b C/T,cell_lines,Experimental Usage,PUB38136356,RES5d59f7d9,USEd30b26e8
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,ipNF95.6,cell_lines,Experimental Usage,PUB38136356,RES53c1db9a,USE869bd8db
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,ipNF02.3 2λ,cell_lines,Experimental Usage,PUB38136356,RES0fc58348,USEf172b7fb
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,ipNF02.8,cell_lines,Experimental Usage,PUB38136356,RES9e84f002,USE56945ca5
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,NF95.11b,cell_lines,Experimental Usage,PUB38216572,RESf59f8ed8,USEd2c25c40
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,NF95.6,cell_lines,Experimental Usage,PUB38216572,RES250e44b5,USE122962ab
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,SNF02.2,cell_lines,Experimental Usage,PUB38216572,RES359bb0bd,USEecf8ac1c
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,SNF94.3,cell_lines,Experimental Usage,PUB38216572,RES920f4fcf,USE012f6371
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,SNF96.2,cell_lines,Experimental Usage,PUB38216572,RES65ffa5bf,USEcf3b028a
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,ST88-14,cell_lines,Experimental Usage,PUB38216572,RES8c79577c,USEa0ce457e
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,JW18.2,cell_lines,Experimental Usage,PUB38216572,RES9723ccfe,USE144c34f3
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,JW23.3,cell_lines,Experimental Usage,PUB38216572,RES80dcb249,USE3c21bd47
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,BenMen-1,cell_lines,Experimental Usage,PUB36148553,RES8ba7d57b,USEafe17462
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,KT21-MG1,cell_lines,Experimental Usage,PUB36148553,RESb1b27a6d,USE43f3f9ce
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,293FT,cell_lines,Experimental Usage,PUB36148553,RESd536c7d1,USE1ed2fe58
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,U251,cell_lines,Experimental Usage,PUB25043298,RES874fed52,USEfb124ff6
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype,,HeLa cells,cell_lines,Experimental Usage,PUB36420221,RES1de4e591,USE2dc107e6
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype,,NF2 primary fibroblasts,cell_lines,Experimental Usage,PUB36420221,RES33a9f0e9,USE2fba8a68
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,Primary human vestibular schwannoma (VS) cell cultures,cell_lines,Experimental Usage,PUB32438526,RESf476bcb6,USEb49a1d20
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,NF90-8,cell_lines,Experimental Usage,PUB18367665,RES7d84433c,USE20fb7243
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,ST88-14,cell_lines,Experimental Usage,PUB18367665,RES8c79577c,USE93f2e602
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,Primary normal rat Schwann cells,cell_lines,Experimental Usage,PUB18367665,RES4140cd3d,USE27fecbe7
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,iSC,cell_lines,Experimental Usage,PUB18367665,RES0f0c862a,USEe72729ca
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,ipNF95.11bC,cell_lines,Experimental Usage,PUB40723243,RES8555ee4e,USE23a2aa08
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,ipnNF95.11c,cell_lines,Experimental Usage,PUB40723243,RESd7276863,USEce3d2f0e
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,ipNF05.5 Single Clone,cell_lines,Experimental Usage,PUB40723243,RESc8a1bf77,USEa1febb11
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,ipNF05.5 Mixed Clones,cell_lines,Experimental Usage,PUB40723243,RES21be72dc,USEec71b29b
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,ST88-14,cell_lines,Experimental Usage,PUB37246765,RES8c79577c,USE509d6b25
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,Nf1flox/flox bone marrow stromal cells,cell_lines,Experimental Usage,PUB25043591,RES3e51adf0,USEfd3aab5b
PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,DH5α bacteria,cell_lines,Experimental Usage,PUB19144871,RES036a0bbd,USE1f5449a4
PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,mouse embryonic fibroblasts (MEFs),cell_lines,Experimental Usage,PUB28392281,RES2ab2c141,USE4f936b92
PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,tail-tip fibroblasts (TTFs),cell_lines,Experimental Usage,PUB28392281,RES642f055b,USE4f4401f3
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,Neural stem cells,cell_lines,Experimental Usage,PUB36241865,RES7b2e113f,USE4c7c56c5
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,Nf2-deficient spinal cord neural progenitor cells,cell_lines,Experimental Usage,PUB24817309,RES07add6ac,USEea71ab71
PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,T265,cell_lines,Experimental Usage,PUB41001593,RES46d7227b,USE4b9292f3
PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,S462,cell_lines,Experimental Usage,PUB41001593,RES7787dd40,USEe9a1e187
PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,NSF1,cell_lines,Experimental Usage,PUB41001593,RESce5c25bd,USE0b1daafb
PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,BRGN,cell_lines,Experimental Usage,PUB41001593,RES93a28363,USE9e553640
PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,primary human Schwann cells (HSC),cell_lines,Experimental Usage,PUB41001593,RESe7efd56d,USE1a2a80bf
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,S462TY,cell_lines,Experimental Usage,PUB38203448,RESba144dfb,USE47815cda
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,STS26T,cell_lines,Experimental Usage,PUB38203448,RES74567322,USEff1573fd
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,T265,cell_lines,Experimental Usage,PUB38203448,RES46d7227b,USE12fb5e42
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,ST8814,cell_lines,Experimental Usage,PUB38203448,RES8c79577c,USE7753b612
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,Normal human Schwann cells (HSC),cell_lines,Experimental Usage,PUB38203448,RES6382be4a,USE6c8cdfc2
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,S462,cell_lines,Experimental Usage,PUB32948135,RES7787dd40,USE7c075a78
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,T265,cell_lines,Experimental Usage,PUB32948135,RES46d7227b,USE8198c540
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,NSF1,cell_lines,Experimental Usage,PUB32948135,RESce5c25bd,USE4c8d54a8
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,B8 fibroblasts,cell_lines,Experimental Usage,PUB32948135,RESb987fd97,USE836511e8
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,STS26T,cell_lines,Experimental Usage,PUB37410426,RES74567322,USE7d40e6a6
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,S462,cell_lines,Experimental Usage,PUB37410426,RES7787dd40,USE21c3eb19
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,ipNF05.5,cell_lines,Experimental Usage,PUB33658640,RES5de742ed,USE5a6901b5
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,95.6,cell_lines,Experimental Usage,PUB33658640,RESea197438,USEf1f054e4
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,ipn02.3,cell_lines,Experimental Usage,PUB33658640,RESfd5f7e36,USE82629228
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,ST88-14,cell_lines,Experimental Usage,PUB33658640,RES8c79577c,USE9fe8886d
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,S462,cell_lines,Experimental Usage,PUB33658640,RES7787dd40,USE1c71882c
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,NF90-8,cell_lines,Experimental Usage,PUB33658640,RES7d84433c,USEc048fdc1
PMID:22811580,10.1158/1078-0432.CCR-12-1072,Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.,,S462-TY,cell_lines,Experimental Usage,PUB22811580,RESba144dfb,USEa2c55e5b
PMID:30796033,10.1158/1078-0432.CCR-18-2437,Overcoming BET Inhibitor Resistance in Malignant Peripheral Nerve Sheath Tumors.,,S462 MPNST cells,cell_lines,Experimental Usage,PUB30796033,RES3dea3292,USE156a8e99
PMID:26657314,10.1371/journal.pone.0144620,Immortalized Human Schwann Cell Lines Derived From Tumors of Schwannomatosis Patients.,,Schwannomatosis cell lines,cell_lines,Development,PUB26657314,RESe5c464c9,USE8e907ffc
PMID:24786638,10.1016/j.ygyno.2014.04.044,Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.,,OVCAR8,cell_lines,Experimental Usage,PUB24786638,RES703cbfa9,USEfd16d81b
PMID:24786638,10.1016/j.ygyno.2014.04.044,Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.,,HEY,cell_lines,Experimental Usage,PUB24786638,RES00610e02,USE65abf18f
PMID:24786638,10.1016/j.ygyno.2014.04.044,Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.,,ID8-IP,cell_lines,Experimental Usage,PUB24786638,RES77cd0d35,USE0270bf4b
PMID:24786638,10.1016/j.ygyno.2014.04.044,Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.,,OVCAR3,cell_lines,Experimental Usage,PUB24786638,RES9949b9ed,USE27a79208
PMID:24786638,10.1016/j.ygyno.2014.04.044,Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.,,OVCAR10,cell_lines,Experimental Usage,PUB24786638,RES07b30759,USEc3a3439d
PMID:24786638,10.1016/j.ygyno.2014.04.044,Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.,,IGROV1,cell_lines,Experimental Usage,PUB24786638,RES69149b19,USEdcf5d1bd
PMID:24786638,10.1016/j.ygyno.2014.04.044,Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.,,IGROV1-IP,cell_lines,Experimental Usage,PUB24786638,RESdaf2e281,USE6d938c34
PMID:24786638,10.1016/j.ygyno.2014.04.044,Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.,,SKOV3,cell_lines,Experimental Usage,PUB24786638,RES9b11a014,USE43c71ca7
PMID:24786638,10.1016/j.ygyno.2014.04.044,Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.,,SKOV3-IP,cell_lines,Experimental Usage,PUB24786638,RESfd4f1b48,USE9a4fcd50
PMID:24786638,10.1016/j.ygyno.2014.04.044,Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.,,A2780,cell_lines,Experimental Usage,PUB24786638,RES75b832f9,USE5cf234b2
PMID:24786638,10.1016/j.ygyno.2014.04.044,Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.,,5009-MOVCAR,cell_lines,Experimental Usage,PUB24786638,RESc27693d8,USE1c89c567
PMID:20739432,10.1158/1078-0432.CCR-10-0613,Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin.,,8814 MPNST cells,cell_lines,Experimental Usage,PUB20739432,RESc0a5d704,USE2d203104
PMID:20739432,10.1158/1078-0432.CCR-10-0613,Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin.,,HUVEC,cell_lines,Experimental Usage,PUB20739432,RESf382497f,USE60d4e68a
PMID:37406085,10.1158/1078-0432.CCR-22-2854,Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma.,,ipNF05.5,cell_lines,Experimental Usage,PUB37406085,RES5de742ed,USE68a45c32
PMID:37406085,10.1158/1078-0432.CCR-22-2854,Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma.,,ipNF95.6,cell_lines,Experimental Usage,PUB37406085,RES53c1db9a,USE96140916
PMID:39620202,10.1093/noajnl/vdae188,Multiomic analyses reveal new targets of polycomb repressor complex 2 in Schwann lineage cells and malignant peripheral nerve sheath tumors.,,iHSCs,cell_lines,Experimental Usage,PUB39620202,RES9da57d39,USEabd26a3b
PMID:39620202,10.1093/noajnl/vdae188,Multiomic analyses reveal new targets of polycomb repressor complex 2 in Schwann lineage cells and malignant peripheral nerve sheath tumors.,,iPNF95.6,cell_lines,Experimental Usage,PUB39620202,RES53c1db9a,USEcc1f467e
PMID:39620202,10.1093/noajnl/vdae188,Multiomic analyses reveal new targets of polycomb repressor complex 2 in Schwann lineage cells and malignant peripheral nerve sheath tumors.,,sNF96.2,cell_lines,Experimental Usage,PUB39620202,RES65ffa5bf,USEe7a5eaa8
PMID:39620202,10.1093/noajnl/vdae188,Multiomic analyses reveal new targets of polycomb repressor complex 2 in Schwann lineage cells and malignant peripheral nerve sheath tumors.,,sNF02.2,cell_lines,Experimental Usage,PUB39620202,RES359bb0bd,USEa91c3d6a
PMID:39620202,10.1093/noajnl/vdae188,Multiomic analyses reveal new targets of polycomb repressor complex 2 in Schwann lineage cells and malignant peripheral nerve sheath tumors.,,26T,cell_lines,Experimental Usage,PUB39620202,RES3806dff7,USEa60dec2c
PMID:39620202,10.1093/noajnl/vdae188,Multiomic analyses reveal new targets of polycomb repressor complex 2 in Schwann lineage cells and malignant peripheral nerve sheath tumors.,,S462TY,cell_lines,Experimental Usage,PUB39620202,RESba144dfb,USEc70e9146
PMID:39620202,10.1093/noajnl/vdae188,Multiomic analyses reveal new targets of polycomb repressor complex 2 in Schwann lineage cells and malignant peripheral nerve sheath tumors.,,ST88-14,cell_lines,Experimental Usage,PUB39620202,RES8c79577c,USE4117532d
PMID:39620202,10.1093/noajnl/vdae188,Multiomic analyses reveal new targets of polycomb repressor complex 2 in Schwann lineage cells and malignant peripheral nerve sheath tumors.,,JH-2-055 CL,cell_lines,Experimental Usage,PUB39620202,RES59a97ec9,USE097a2ca4
PMID:39620202,10.1093/noajnl/vdae188,Multiomic analyses reveal new targets of polycomb repressor complex 2 in Schwann lineage cells and malignant peripheral nerve sheath tumors.,,JH-2-079c CL,cell_lines,Experimental Usage,PUB39620202,RES30d3ea15,USE68feb22b
PMID:39620202,10.1093/noajnl/vdae188,Multiomic analyses reveal new targets of polycomb repressor complex 2 in Schwann lineage cells and malignant peripheral nerve sheath tumors.,,JH-2-003 CL,cell_lines,Experimental Usage,PUB39620202,RES40bdc7d8,USEc9b4609f
PMID:39620202,10.1093/noajnl/vdae188,Multiomic analyses reveal new targets of polycomb repressor complex 2 in Schwann lineage cells and malignant peripheral nerve sheath tumors.,,JH-2-002 CL,cell_lines,Experimental Usage,PUB39620202,RES5bc5ab39,USEda3f25c6
PMID:39620202,10.1093/noajnl/vdae188,Multiomic analyses reveal new targets of polycomb repressor complex 2 in Schwann lineage cells and malignant peripheral nerve sheath tumors.,,CUTLL1,cell_lines,Experimental Usage,PUB39620202,RES7d62064c,USE6d8f0fd1
PMID:39620202,10.1093/noajnl/vdae188,Multiomic analyses reveal new targets of polycomb repressor complex 2 in Schwann lineage cells and malignant peripheral nerve sheath tumors.,,MDA-MB-231,cell_lines,Experimental Usage,PUB39620202,RES3eea2fb8,USEd78aa225
PMID:39620202,10.1093/noajnl/vdae188,Multiomic analyses reveal new targets of polycomb repressor complex 2 in Schwann lineage cells and malignant peripheral nerve sheath tumors.,,MCF7,cell_lines,Experimental Usage,PUB39620202,RES1945f01f,USE02ead1c5
PMID:39016685,10.1242/jcs.262343,Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss.,,U87-MG,cell_lines,Experimental Usage,PUB39016685,RES02cd4945,USE93dc5ddf
PMID:39016685,10.1242/jcs.262343,Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss.,,U251-MG,cell_lines,Experimental Usage,PUB39016685,RESeecc33e0,USE480611da
PMID:39016685,10.1242/jcs.262343,Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss.,,sNF96.2,cell_lines,Experimental Usage,PUB39016685,RES65ffa5bf,USE6b79c705
PMID:39016685,10.1242/jcs.262343,Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss.,,ipnNF95.11C,cell_lines,Experimental Usage,PUB39016685,RESd7276863,USE989264d7
PMID:39016685,10.1242/jcs.262343,Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss.,,ipNF95.11b 'C',cell_lines,Experimental Usage,PUB39016685,RES8555ee4e,USE5f1e3a2d
PMID:39016685,10.1242/jcs.262343,Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss.,,Immortalized mammary epithelial cells (IMECs),cell_lines,Experimental Usage,PUB39016685,RES82959a23,USEe422a9dc
PMID:25877069,10.1007/s11626-015-9885-z,Establishment of immortalized murine mesothelial cells and a novel mesothelioma cell line.,,RN5 cell line,cell_lines,Development,PUB25877069,RESc76207ba,USE0a0e1b84
PMID:25877069,10.1007/s11626-015-9885-z,Establishment of immortalized murine mesothelial cells and a novel mesothelioma cell line.,,AK7 cell line,cell_lines,Experimental Usage,PUB25877069,RESd8cdcdcd,USEce077f40
PMID:33574490,10.1038/s41598-021-83152-w,Using antisense oligonucleotides for the physiological modulation of the alternative splicing of NF1 exon 23a during PC12 neuronal differentiation.,,PC12 cells (ATCC CRL-1721),cell_lines,Experimental Usage,PUB33574490,RES1edc0455,USE463a01cb
PMID:33574490,10.1038/s41598-021-83152-w,Using antisense oligonucleotides for the physiological modulation of the alternative splicing of NF1 exon 23a during PC12 neuronal differentiation.,,H19-7/IGF-IR (ATCC CRL-2526),cell_lines,Experimental Usage,PUB33574490,RES0413528a,USE0ee231db
PMID:21697395,10.1158/1535-7163.MCT-11-0309,Discovery of a small molecule targeting IRA2 deletion in budding yeast and neurofibromin loss in malignant peripheral nerve sheath tumor cells.,,STS26T,cell_lines,Experimental Usage,PUB21697395,RES74567322,USEf897304d
PMID:21697395,10.1158/1535-7163.MCT-11-0309,Discovery of a small molecule targeting IRA2 deletion in budding yeast and neurofibromin loss in malignant peripheral nerve sheath tumor cells.,,T265,cell_lines,Experimental Usage,PUB21697395,RES46d7227b,USE6a4b6e84
PMID:30713041,10.1016/j.stemcr.2019.01.001,Reprogramming Captures the Genetic and Tumorigenic Properties of Neurofibromatosis Type 1 Plexiform Neurofibromas.,,NF1(-/-)-induced pluripotent stem cells,cell_lines,Development,PUB30713041,RES310fed3d,USE93b1ee9c
PMID:30713041,10.1016/j.stemcr.2019.01.001,Reprogramming Captures the Genetic and Tumorigenic Properties of Neurofibromatosis Type 1 Plexiform Neurofibromas.,,iPSC-derived NF1(-/-) SCs,cell_lines,Development,PUB30713041,RESc8a90b5e,USEdff10ee9
PMID:36799629,10.1158/1078-0432.CCR-22-3722,MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors.,,JH-2–002 cells,cell_lines,Experimental Usage,PUB36799629,RES06bbbd46,USE534f5a97
PMID:36799629,10.1158/1078-0432.CCR-22-3722,MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors.,,MPNST-724 cells,cell_lines,Experimental Usage,PUB36799629,RESab623eca,USE94b11ce1
PMID:36799629,10.1158/1078-0432.CCR-22-3722,MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors.,,JW23.3 cells,cell_lines,Experimental Usage,PUB36799629,RES80dcb249,USEfbee6bc8
PMID:28065690,10.1016/j.biochi.2017.01.001,Medium throughput biochemical compound screening identifies novel agents for pharmacotherapy of neurofibromatosis type 1.,,MEF Nf1−/− E1A-p53,cell_lines,Experimental Usage,PUB28065690,RESc7e85be1,USE5cf2bd41
PMID:28065690,10.1016/j.biochi.2017.01.001,Medium throughput biochemical compound screening identifies novel agents for pharmacotherapy of neurofibromatosis type 1.,,MEF Nf1wt E1A-p53,cell_lines,Experimental Usage,PUB28065690,RES4a01ef13,USEd5f1bc92
PMID:28065690,10.1016/j.biochi.2017.01.001,Medium throughput biochemical compound screening identifies novel agents for pharmacotherapy of neurofibromatosis type 1.,,sNF96.2,cell_lines,Experimental Usage,PUB28065690,RES65ffa5bf,USE4d6a652c
PMID:28065690,10.1016/j.biochi.2017.01.001,Medium throughput biochemical compound screening identifies novel agents for pharmacotherapy of neurofibromatosis type 1.,,sNF02.2,cell_lines,Experimental Usage,PUB28065690,RES359bb0bd,USE803a5ee5
PMID:28065690,10.1016/j.biochi.2017.01.001,Medium throughput biochemical compound screening identifies novel agents for pharmacotherapy of neurofibromatosis type 1.,,sNF94.3,cell_lines,Experimental Usage,PUB28065690,RES920f4fcf,USE3634d770
PMID:28065690,10.1016/j.biochi.2017.01.001,Medium throughput biochemical compound screening identifies novel agents for pharmacotherapy of neurofibromatosis type 1.,,S462TY,cell_lines,Experimental Usage,PUB28065690,RESba144dfb,USE55444f92
PMID:28065690,10.1016/j.biochi.2017.01.001,Medium throughput biochemical compound screening identifies novel agents for pharmacotherapy of neurofibromatosis type 1.,,ST8814,cell_lines,Experimental Usage,PUB28065690,RES8c79577c,USEa438d631
PMID:28065690,10.1016/j.biochi.2017.01.001,Medium throughput biochemical compound screening identifies novel agents for pharmacotherapy of neurofibromatosis type 1.,,ST88-3,cell_lines,Experimental Usage,PUB28065690,RES8fd7beb2,USE1a54abb6
PMID:28065690,10.1016/j.biochi.2017.01.001,Medium throughput biochemical compound screening identifies novel agents for pharmacotherapy of neurofibromatosis type 1.,,90-8,cell_lines,Experimental Usage,PUB28065690,RES4d55b268,USE4610c871
PMID:19427294,10.1016/j.stem.2009.03.017,Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas.,,3T3 cells,cell_lines,Experimental Usage,PUB19427294,RES69492189,USEfc0ad97d
PMID:19041782,10.1016/j.stem.2008.10.003,Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential.,,293T cells,cell_lines,Experimental Usage,PUB19041782,RES63f2af1e,USE69ed5f88
PMID:29137242,10.18632/oncotarget.18301,Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy.,,S462TY,cell_lines,Experimental Usage,PUB29137242,RESba144dfb,USE699a1682
PMID:29137242,10.18632/oncotarget.18301,Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy.,,STS-26T,cell_lines,Experimental Usage,PUB29137242,RES74567322,USE1715e6fd
PMID:29662612,10.18632/oncotarget.19335,Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells.,,U87-MG,cell_lines,Experimental Usage,PUB29662612,RES02cd4945,USE52adf9c6
PMID:29662612,10.18632/oncotarget.19335,Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells.,,U251-MG,cell_lines,Experimental Usage,PUB29662612,RESeecc33e0,USEb3741028
PMID:37616542,10.1158/1535-7163.MCT-23-0258,"Pro-905, a Novel Purine Antimetabolite, Combines with Glutamine Amidotransferase Inhibition to Suppress Growth of Malignant Peripheral Nerve Sheath Tumor.",,sNF96.2,cell_lines,Experimental Usage,PUB37616542,RES65ffa5bf,USEecc9e66f
PMID:37616542,10.1158/1535-7163.MCT-23-0258,"Pro-905, a Novel Purine Antimetabolite, Combines with Glutamine Amidotransferase Inhibition to Suppress Growth of Malignant Peripheral Nerve Sheath Tumor.",,JH-2–002,cell_lines,Experimental Usage,PUB37616542,RES06bbbd46,USE6ffeb07d
PMID:37616542,10.1158/1535-7163.MCT-23-0258,"Pro-905, a Novel Purine Antimetabolite, Combines with Glutamine Amidotransferase Inhibition to Suppress Growth of Malignant Peripheral Nerve Sheath Tumor.",,JH-2–031,cell_lines,Experimental Usage,PUB37616542,RES748525c7,USE4ca74f03
PMID:19306381,10.1002/glia.20866,Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.,,YST-1,cell_lines,Experimental Usage,PUB19306381,RESc41540f6,USE0addbd2a
PMID:19306381,10.1002/glia.20866,Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.,,STS-26T,cell_lines,Experimental Usage,PUB19306381,RES74567322,USEdf249d3a
PMID:19306381,10.1002/glia.20866,Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.,,ST88-14,cell_lines,Experimental Usage,PUB19306381,RES8c79577c,USEb6900627
PMID:19306381,10.1002/glia.20866,Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.,,A202,cell_lines,Experimental Usage,PUB19306381,RESefa1899f,USE66df1f32
PMID:19306381,10.1002/glia.20866,Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.,,B76,cell_lines,Experimental Usage,PUB19306381,RES7ba5993a,USE71c736fd
PMID:19306381,10.1002/glia.20866,Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.,,B97,cell_lines,Experimental Usage,PUB19306381,RES80250081,USE5a7b2db8
PMID:18931645,10.1097/MAO.0b013e31818b6cea,Bioluminescent imaging of intracranial vestibular schwannoma xenografts in NOD/SCID mice.,,293T cells,cell_lines,Experimental Usage,PUB18931645,RES63f2af1e,USE71f8c37c
PMID:41616055,10.1126/sciadv.ady8382,Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis.,,hTERT ipn02.3 2l SCs,cell_lines,Experimental Usage,PUB41616055,RESb74512da,USE79288dde
PMID:41616055,10.1126/sciadv.ady8382,Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis.,,HEI-193 schwannoma,cell_lines,Experimental Usage,PUB41616055,RES8a9a3d50,USE89fe8f93
PMID:41616055,10.1126/sciadv.ady8382,Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis.,,MS03 schwannoma,cell_lines,Experimental Usage,PUB41616055,RES04fb6de4,USE69e12c9d
PMID:18927496,10.4161/cbt.7.12.6942,Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.,,ST88-14,cell_lines,Experimental Usage,PUB18927496,RES8c79577c,USE4e8f934c
PMID:18927496,10.4161/cbt.7.12.6942,Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.,,NF90-8,cell_lines,Experimental Usage,PUB18927496,RES7d84433c,USE9056f8f6
PMID:18927496,10.4161/cbt.7.12.6942,Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.,,STS-26T,cell_lines,Experimental Usage,PUB18927496,RES74567322,USE50563967
PMID:38811427,10.1186/s41687-024-00732-w,Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,,cNF-Skindex,clinical_assessment_tools,Experimental Usage,PUB38811427,RES957dce31,USEe5aa7976
PMID:28193237,10.1186/s12955-017-0607-y,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,,Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire,clinical_assessment_tools,Development,PUB28193237,RESeffc3820,USEbd1864a7
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,Cirrus HD-OCT,clinical_assessment_tools,Experimental Usage,PUB38990917,RESa1301f77,USEb3f6f962
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,Teller acuity cards,clinical_assessment_tools,Experimental Usage,PUB38990917,REScf856181,USE1de06c15
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,Cardiff acuity cards,clinical_assessment_tools,Experimental Usage,PUB38990917,RES9cacf8bc,USE7ffcebc3
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,Lea cards,clinical_assessment_tools,Experimental Usage,PUB38990917,RESdb522b86,USE43b115f7
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,KM (Konstantin Moutakis) cards,clinical_assessment_tools,Experimental Usage,PUB38990917,RES52bd88fc,USE2e311d10
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,Humphrey Field Analyzer perimetry,clinical_assessment_tools,Experimental Usage,PUB38990917,RESce67dd2f,USE4fc5e063
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,World Health Organization Categories of Childhood VI scale,clinical_assessment_tools,Experimental Usage,PUB38990917,RESc9cd8d77,USE9af56eba
PMID:40737523,10.2196/71728,Clinician Perspectives of a Magnetic Resonance Imaging-Based 3D Volumetric Analysis Tool for Neurofibromatosis Type 2-Related Schwannomatosis: Qualitative Pilot Study.,,Likert scale questionnaire,clinical_assessment_tools,Experimental Usage,PUB40737523,RES19135a16,USEf1fadf5e
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,,BoN (Burden of NF1) questionnaire,clinical_assessment_tools,Development,PUB31053133,RES3d1c5b79,USE6e0c47f0
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,,Dermatology Life Quality Index (DLQI),clinical_assessment_tools,Experimental Usage,PUB31053133,RESa9713e90,USE2d089f26
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,,SF12,clinical_assessment_tools,Experimental Usage,PUB31053133,RES0f6ab480,USE54dafaa0
PMID:38499890,10.1186/s41687-024-00714-y,"The PlexiQoL, a patient-reported outcome measure on quality of life in neurofibromatosis type 1-associated plexiform neurofibroma: translation, cultural adaptation and validation into the Dutch language for the Netherlands.",,PlexiQoL,clinical_assessment_tools,Experimental Usage,PUB38499890,RES6496c902,USEedc1620f
PMID:33085177,10.1002/mgg3.1530,The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.,,PlexiQoL,clinical_assessment_tools,Development,PUB33085177,RES6496c902,USE3091930f
PMID:34106871,10.1109/JBHI.2021.3087735,DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI.,,DINs (Deep Interactive Networks),computational_tools,Development,PUB34106871,RESda500560,USEc4be654d
PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,RENOVO-NF1,computational_tools,Development,PUB40887659,RES5b11eb44,USE709185ef
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,shNF1,genetic_reagents,Experimental Usage,PUB35589737,RESe7247e8c,USE4e5f391d
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,NF1 gRNA,genetic_reagents,Experimental Usage,PUB38216123,RES97ca2fea,USEdc7460f1
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,NF1 isoform 2,genetic_reagents,Experimental Usage,PUB31836666,RES4701a839,USE873011de
PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,NF2,genetic_reagents,Experimental Usage,PUB24595234,RESc7f2e43a,USE634d6988
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,SPRED1,genetic_reagents,Experimental Usage,PUB40225167,RESc85d1396,USE7e985367
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,Merlin,genetic_reagents,Experimental Usage,PUB32457840,RES11f352ff,USE90bdb38d
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,NF2,genetic_reagents,Experimental Usage,PUB33273014,RESc7f2e43a,USE326f9cd3
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,dNf1,genetic_reagents,Experimental Usage,PUB39129390,RESdcd0e8c4,USEf1fa606e
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,Nf2,genetic_reagents,Experimental Usage,PUB29715273,RESc7f2e43a,USE6b8639af
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,NF1-GRD,genetic_reagents,Experimental Usage,PUB24509877,RESe1af3877,USEfba09607
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,Nf1,genetic_reagents,Experimental Usage,PUB39890807,RES5b74c968,USE387000d2
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,NF1-targeting TALEN,genetic_reagents,Experimental Usage,PUB37520682,RES17bd5adf,USE3186b6ad
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,NF1 DLR,genetic_reagents,Experimental Usage,PUB37520682,RES635b74af,USEcfa1dec4
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,Nf1 flox,genetic_reagents,Experimental Usage,PUB22901811,RESc54d4fe5,USE8feefad9
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,Nf1 KO,genetic_reagents,Experimental Usage,PUB22901811,RES42a9482e,USEa913495c
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,NF1,genetic_reagents,Experimental Usage,PUB38481529,RES5b74c968,USE0408e5fa
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,NF1,genetic_reagents,Experimental Usage,PUB38481529,RES5b74c968,USE0408e5fa
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,human neurofibromin,genetic_reagents,Experimental Usage,PUB40590220,RES3c86e21c,USE00e1c30f
PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,NF1 capture probes,genetic_reagents,Experimental Usage,PUB27999334,RESb42186d8,USE3754d4f7
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,neurofibromin 2,genetic_reagents,Experimental Usage,PUB20195187,RESf228eeaf,USE06646844
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,NF2 shRNA,genetic_reagents,Experimental Usage,PUB30274821,RES0c4385ea,USEb00bc68a
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,NF2,genetic_reagents,Experimental Usage,PUB30274821,RESc7f2e43a,USE1a5aa499
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,NF1,genetic_reagents,Experimental Usage,PUB37446790,RES5b74c968,USE806bad04
PMID:28831766,10.1007/s12104-017-9768-1,NMR resonance assignments of the EVH1 domain of neurofibromin's recruitment factor Spred1.,,Spred1(EVH1),genetic_reagents,Experimental Usage,PUB28831766,RES66e53bd9,USE3e31d8bf
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,NF1 isoform-2,genetic_reagents,Experimental Usage,PUB36689660,RES4701a839,USE805ab539
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,NF1-GRD,genetic_reagents,Experimental Usage,PUB38000020,RESe1af3877,USE8b849cac
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,NF1,genetic_reagents,Experimental Usage,PUB34011935,RES5b74c968,USE2b931e6f
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,NF2,genetic_reagents,Experimental Usage,PUB26219339,RESc7f2e43a,USEed35b8b9
PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,NF2 TET,genetic_reagents,Experimental Usage,PUB18974932,RES23ac5668,USE83ba05b6
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,Merlin isoform 1,genetic_reagents,Experimental Usage,PUB24882693,RES23b2c1c0,USE320f9c20
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,Merlin(S518D) and Merlin(S518E) mutants,genetic_reagents,Experimental Usage,PUB24882693,RES2f3f2a53,USE18ab2e9a
PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,NF1,genetic_reagents,Experimental Usage,PUB37140985,RES5b74c968,USE000739d1
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,Merlin siRNA,genetic_reagents,Experimental Usage,PUB25043298,RESf0456171,USE830c0184
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,HA-Merlin,genetic_reagents,Experimental Usage,PUB25043298,RESd9daee7e,USEb485833f
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,S518A HA-Merlin,genetic_reagents,Experimental Usage,PUB25043298,RES7ba0612d,USEf471b8ec
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,nf2a/b-4sgRNA,genetic_reagents,Experimental Usage,PUB39415595,RES39306a69,USE8b7fe087
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,NF1 GRD,genetic_reagents,Experimental Usage,PUB16835260,RESe1af3877,USE55e7bee7
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,1276P NF1 GRD,genetic_reagents,Experimental Usage,PUB16835260,RESdfd13d05,USE94620d73
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,Cas9 and sgRNAs targeting Nf1+Cdkn2a,genetic_reagents,Experimental Usage,PUB37410426,RES0829546a,USEaf0a56af
PMID:24786638,10.1016/j.ygyno.2014.04.044,Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.,,NF2 shRNA,genetic_reagents,Experimental Usage,PUB24786638,RES0c4385ea,USE0eff77ad
PMID:32443592,10.3390/ijms21103569,C-Fiber Loss as a Possible Cause of Neuropathic Pain in Schwannomatosis.,,NF2,genetic_reagents,Experimental Usage,PUB32443592,RESc7f2e43a,USE0466e7c0
PMID:30290804,10.1186/s12929-018-0474-9,Genetic diagnosis of neurofibromatosis type 1: targeted next- generation sequencing with Multiple Ligation-Dependent Probe Amplification analysis.,,NF1 MLPA probes,genetic_reagents,Experimental Usage,PUB30290804,RESd3635ee1,USE37ba6a6e
PMID:33279959,10.1093/brain/awaa404,"Stepwise crosstalk between aberrant Nf1, Tp53 and Rb signalling pathways induces gliomagenesis in zebrafish.",,nf1a gRNA,genetic_reagents,Development,PUB33279959,RES90279a0b,USEb463c79b
PMID:26066488,10.1371/journal.pone.0129099,A Systematic Assessment of Accuracy in Detecting Somatic Mosaic Variants by Deep Amplicon Sequencing: Application to NF2 Gene.,,NF2 MLPA,genetic_reagents,Experimental Usage,PUB26066488,RES5f0b44a7,USE8eacd0ba
PMID:41616055,10.1126/sciadv.ady8382,Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis.,,NF2,genetic_reagents,Experimental Usage,PUB41616055,RESc7f2e43a,USE4e686dec
PMID:29590612,10.1016/j.celrep.2018.03.014,A Conserved Circadian Function for the Neurofibromatosis 1 Gene.,,P2 Nf1,genetic_reagents,Experimental Usage,PUB29590612,RES42225466,USEbc8b336a
PMID:16314489,10.1242/dev.02162,Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation.,,Nf1flox,genetic_reagents,Experimental Usage,PUB16314489,RESc54d4fe5,USEeb635cb7
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,JH-2-002,patient_derived_models,Experimental Usage,PUB41022755,RES16a23407,USEed605a06
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,JH-2-031,patient_derived_models,Experimental Usage,PUB41022755,RESdf3c4127,USE170621bb
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,JH-2-002 PDX,patient_derived_models,Experimental Usage,PUB38000020,RES16a23407,USEcfcb6e68
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,JH-2-031 PDX,patient_derived_models,Experimental Usage,PUB38000020,RESdf3c4127,USE955acd6d
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,JH-2-079c PDX,patient_derived_models,Experimental Usage,PUB38000020,RES0443ac87,USEfcedb4cb
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,WU-225 PDX,patient_derived_models,Experimental Usage,PUB38000020,RES537ef440,USE4b3fc7fb
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,WU-386 PDX,patient_derived_models,Experimental Usage,PUB38000020,RES9e22d7dd,USE12745c6d
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,WU-545 PDX,patient_derived_models,Experimental Usage,PUB38000020,RES9e54235e,USEb6f73454
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,MN-2 PDX,patient_derived_models,Experimental Usage,PUB38000020,RES0009d5c2,USE3e20e56c
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,MN-3-002 PDX,patient_derived_models,Experimental Usage,PUB38000020,RES3bee3866,USE0cb26c19
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,Patient-derived xenograft (PDX) MPNST model,patient_derived_models,Experimental Usage,PUB41036607,RES1c4e8ce2,USEb415bf6c
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,MPNST-SP-01 PDOX,patient_derived_models,Experimental Usage,PUB35511749,RESf0162f34,USE6a3eda3b
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,MPNST-NF1-09 PDOX,patient_derived_models,Experimental Usage,PUB35511749,RESdd3ae49a,USEab54bb06
PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,vestibular schwannoma xenografts,patient_derived_models,Experimental Usage,PUB18636037,RES458f9b63,USE6908e058
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,JH-2–002,patient_derived_models,Experimental Usage,PUB33032988,RES16a23407,USEff9c709b
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,JH-2–009,patient_derived_models,Experimental Usage,PUB33032988,RESc49f4ec1,USEafa31a0b
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,JH-2–031,patient_derived_models,Experimental Usage,PUB33032988,RESdf3c4127,USE1c6159bc
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,JH-2–055,patient_derived_models,Experimental Usage,PUB33032988,RES4fff48c1,USE00c65be0
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,JH-2–060,patient_derived_models,Experimental Usage,PUB33032988,RES018791d0,USE550e5099
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,JH-2–074,patient_derived_models,Experimental Usage,PUB33032988,RESdd043a79,USE5fe1a34a
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,JH-2–077,patient_derived_models,Experimental Usage,PUB33032988,RES8cd0e8db,USE2d6f96f8
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,PDX JH-2–002,patient_derived_models,Experimental Usage,PUB33032988,RES16a23407,USEadbcc215
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,Cutaneous neurofibroma samples,patient_derived_models,Experimental Usage,PUB38744290,RES467d7d57,USE89461185
PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,,human neurofibroma xenografts,patient_derived_models,Experimental Usage,PUB15240917,RES09dbe9c5,USEca810e3b
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,RHT-92,patient_derived_models,Experimental Usage,PUB33658640,RES8f664fbf,USEcc1c0721
PMID:22811580,10.1158/1078-0432.CCR-12-1072,Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.,,NF1−/− S462-TY human MPNST xenograft,patient_derived_models,Experimental Usage,PUB22811580,RES4ae27e8f,USEd4b2e937
PMID:39620202,10.1093/noajnl/vdae188,Multiomic analyses reveal new targets of polycomb repressor complex 2 in Schwann lineage cells and malignant peripheral nerve sheath tumors.,,MPNST724,patient_derived_models,Experimental Usage,PUB39620202,RES7ef908c6,USE688791b0
PMID:39620202,10.1093/noajnl/vdae188,Multiomic analyses reveal new targets of polycomb repressor complex 2 in Schwann lineage cells and malignant peripheral nerve sheath tumors.,,MPNST007,patient_derived_models,Experimental Usage,PUB39620202,RES6b2e4168,USE5dddc33d
PMID:36799629,10.1158/1078-0432.CCR-22-3722,MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors.,,WU-386 PDX line,patient_derived_models,Experimental Usage,PUB36799629,RESa52d99d4,USE141b7b20
PMID:37616542,10.1158/1535-7163.MCT-23-0258,"Pro-905, a Novel Purine Antimetabolite, Combines with Glutamine Amidotransferase Inhibition to Suppress Growth of Malignant Peripheral Nerve Sheath Tumor.",,JH-2–031 MPNST PDX,patient_derived_models,Experimental Usage,PUB37616542,RES973c5f48,USE2515305b
PMID:18931645,10.1097/MAO.0b013e31818b6cea,Bioluminescent imaging of intracranial vestibular schwannoma xenografts in NOD/SCID mice.,,Patient excised vestibular schwannomas,patient_derived_models,Experimental Usage,PUB18931645,RES29cd8c80,USE81b3443b
